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General Introduction 
1. Anxiety 
1.1 Anxiety disorders 
Anxiety is an adaptive, evolutionary conserved response to frightening stimuli. These stimuli 
often initiate a stress response, characterized by the activation of the hypothalamo-
pituitary-adrenal (HPA) axis and subsequent secretion of adrenal steroids (Aguilera 1998). 
This leads to increased heart rate, vigilance, a decrease in feeding, and exploration of the 
environment (Korte 2001). However, if anxiety becomes excessive, it poses a threat to a 
person’s or animal’s mental well-being and then falls under the classification of anxiety 
disorders. About 18 % of the American adults and 14 % of EU citizens were affected by 
anxiety disorders in 2010 (Wittchen et al. 2011), which include panic disorders, obsessive-
compulsive disorder, post-traumatic stress disorder, social anxiety disorder, and generalized 
anxiety disorder. Such high numbers imply the need for efficient medication. However, 
current treatments, such as the use of benzodiazepines and selective serotonin re-uptake 
inhibitors (SSRIs), are not fully satisfactory because of addictive effects, development of 
tolerance, and poor efficacy in a subset of patients. Therefore, new anxiolytic drugs are 
needed and unraveling the molecular mechanisms of anxiety regulation in the brain could 
contribute to the quest for proper medication. Current research in this field is devoted to 
finding genes that are important for anxiety and stress. 
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1.2 Anxiety-related genes 
In recent years, some candidate genes have been found to be involved in the regulation of 
anxiety and, if dys-regulated, may cause anxiety disorders (Hovatta and Barlow 2008). These 
genes are involved, for example, in the regulation of G-protein signaling (Rgs2), GABA A 
receptor regulation (Gabra2), neurotrophic factor signaling (TrkB), peroxisome proliferator-
activated receptor gamma coactivator 1 alpha (Ppargc1a) signaling, opioid µ-receptor 
signaling (Opmr1) (Sokolowska and Hovatta 2013), or in HPA axis regulation and dendritic 
spine formation (corticotrophin releasing factor; CRF) (Maras and Baram 2012). Also, several 
other anxiety-relevant genes that code for neuropeptides are involved in the regulation of 
anxiety and stress, such as the neuropeptide Y (Giesbrecht et al. 2010), neuropeptide S 
(Ionescu et al. 2012), substance P (Ebner and Singewald 2006), nociceptin/orphanin FQ 
(Martin-Fardon et al. 2010), arginine-vasopressin (AVP), and oxytocin (OT) (Neumann and 
Landgraf 2012) to name a few. The plethora of neuropeptides regulating an organism’s 
stress and anxiety response is necessary to fine-tune the response to the apparent stressor. 
It lies beyond the scope of this work to address all anxiety and stress-related neuropeptides; 
the focus will be therefore on CRF and OT. The transcriptional regulation of CRF was 
intensely studied in this work, because it has anxiogenic properties when it is released in the 
amygdala (Mountney et al. 2011). Furthermore, it is the first factor in the HPA axis and 
therefore an important stress-related neuropeptide.  
Another factor that relates to this work is Rgs2, whose transcription is regulated by the 
neuropeptide OT (Okimoto et al. 2012), and, in a different context, via the CREB 
transcriptional coactivator 3 (CRTC3) (see below) (Song et al. 2010). It is thus possible that 
OT controls the expression of genes related to anxiety and stress by modulating a CRTC-
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dependent pathway. This is one of the hypotheses that were tested in the work presented 
here.  
 
1.3 Anxiety-related behavior in animal models 
Although identification of genes involved in anxiety is useful, it has become more and more 
accepted over the years that one single gene is unlikely to be the regulator of complex 
emotions like anxiety. It is more likely the combination of psychological/environmental 
factors (stress), and the genetic predisposition that underlies the individual’s susceptibility 
for developing anxiety disorders (Bakshi and Kalin 2000; Razafsha et al. 2013). Nevertheless, 
the genetic background is one important factor in the etiology of anxiety disorders and can 
be studied using a variety of methods like genome-wide expression profiling, proteomics, or 
quantitative trait locus mapping (Sokolowska and Hovatta 2013). To investigate the 
involvement of these genes in anxiety-like behavior several behavioral test paradigms, such 
as the elevated plus maze, open field test, light dark box (LDB), and novelty suppressed 
feeding test can be applied (Sokolowska and Hovatta 2013).  
To assess the effects of OT on non-social anxiety-related behavior in my rat studies I 
monitored rats in the LDB. This test makes use of a conflict the rats will experience, i.e. the 
rats’ exploratory drive versus the fear of open and bright spaces. Therefore, the more time a 
rat spends in the bright compartment of the LDB, the less anxious it is.  
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2. The neuropeptide oxytocin (OT) 
In the search for endogenous anxiolytic factors, the neuropeptide OT was discovered to 
exert anxiolytic activity in the central amygdala (CeA) of rats in 2001 (Bale et al. 2001). It is 
produced only in two hypothalamic nuclei, the supraoptic and the paraventricular nuclei 
(PVN), from where it is distributed by axonal projections (Knobloch et al. 2011) and, more 
locally, dendritic release and diffusion (Landgraf and Neumann 2004; Ludwig and Leng 
2006). OT, known as the “love, trust or cuddle hormone”, is also available as a nasal spray, 
which has been reported to increase trust and to reduce cortisol levels during couple 
conflicts in humans (Kosfeld et al. 2005; Ditzen et al. 2009). When released in the brain, it 
has been well acknowledged for its regulation of reproductive behavior, such as maternal 
care and aggression, pair bonding, sexual behavior and anxiety-like behavior (Bosch et al. 
2005; Bales et al. 2007; Waldherr and Neumann 2007). Further studies in humans revealed a 
role for OT in enhancing the individuals’ social skills and to antagonize depression, post-
traumatic stress disorder, autism, and other psychiatric illnesses. However, OT also 
stimulates aggression against group-outsiders, selfish behavior depending on the social 
context, personality, and gender (Bakermans-Kranenburg 2013) and can even be fear-
enhancing (Guzman et al. 2013). The molecular underpinnings of this wide range of 
behavioral effects are rather unknown and under intense scientific investigation. To reveal 
some of these molecular mechanisms of OT actions was, therefore, in the focus of this 
thesis. 
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2.1 Central and peripheral OT release 
Neuropeptides are amino acid assemblies that are synthesized on ribosomes in the 
cytoplasm, packed into Golgi vesicles and post-translationally modified in their transport 
vesicles. Neuronal dendrites are capable of synthesizing neuropeptides, such as OT, to allow 
fast dendritic release, while axonal synthesis could not be observed (Tiedge et al. 1999). 
Although peripheral release of OT from the neurohypophysis into blood is under the control 
of a variety of stimuli and neurotransmitters, noradrenaline (norepinephrine), histamine, 
and excitatory amino acids have been directly associated with peripheral release, especially 
in response to suckling. More recent studies revealed the involvement of these 
neurotransmitters in the regulation of central release of OT as well (for review see (Bealer et 
al. 2010)). Following an appropriate stimulus, OT is centrally released from either axon 
terminals as a rapid synaptic neurotransmitter (Dabrowska et al. 2011), or from dendrites, 
soma, or non-terminal axonal regions as a non-synaptic neuromodulator (Tobin et al. 2012). 
A neuromodulator is recognized by slow substance diffusion via the extracellular fluid, and 
binding to nearby or distant receptors in brain regions that are not necessarily connected via 
axonal projections. Interestingly, central release and peripheral release from 
neurohypophysial terminals into the blood stream can be either independent or 
coordinated, depending on the type of stimulus (Neumann and Landgraf 2012). Stimuli like 
birth, suckling, sexual activity, and a variety of stressors trigger coordinated central and 
peripheral release of OT, whereas other stressors, such as social defeat, exclusively trigger 
central release without altering peripheral levels (Engelmann et al. 1999; Landgraf and 
Neumann 2004). This differential release of a neuropeptide from separate compartments of 
a single neuron implies the need for fine-tuned regulatory mechanisms. Somato-dendritic, 
but not axon terminal release, is triggered by depolarization-induced release of calcium 
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(Ca2+) from intracellular stores via voltage operated Ca2+ channels (VOCCs), which leads to 
the depolymerization of filamentous (F)-actin to monomer G-actin. F-actin is a barrier for 
Large Dense Core Vesicles (LDCV), which prevents exocytosis at the cell membrane, whereas 
depolymerized G-actin allows fusion of LDCV with the membrane and subsequent exocytosis 
of incorporated neuropeptides. Binding of OT to the OT receptor (OTR) leads to a rise in 
intracellular Ca2+ levels, which induces “priming” of the OT neuron for potentiated dendritic 
OT release (Ludwig et al. 2002). However, the physiological meaning of this self-potentiated 
dendritic release is not yet fully understood. 
The classical action potential-driven axonal release from neurohypophysial terminals into 
the blood stream leads to the well-known peripheral effects of OT, like induction of labour 
or milk ejection.  
 
Figure 1 The brain OT system: neuronal projections, release, receptor-mediated effects, and external 
application. In brief, central release of OT as a neuromodulator occurs from dendrites and perikarya, in 
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addition to axon terminal release as a neurotransmitter. Central release can occur independently and 
simultaneously of peripheral release. Taken and adapted from (Neumann and Landgraf 2012) 
 
 
 
 
 
 
 
2.2 The OTR and OTR-coupled signaling cascades 
All of the effects that OT exerts on animal behavior and physiology, including its anxiolytic 
activity, are the consequence of its binding to the OTR and the subsequent induction of 
intracellular physiological responses. The OTR is a 7-trans-membrane domain class I G-
protein coupled receptor (GPCR). The human OTR gene consists of 4 exons and 3 introns, 
and the promoter consists of a variety of species-dependent transcription factor binding 
sites. The OTR gene is differentially expressed in various tissues and under different 
physiologic conditions (virgin vs. post-partum), regulated by DNA methylation of a specific 
CpG site in the promoter (Mamrut et al. 2013). The sequence homology between the 
mammalian OTR and vasopressin receptor 1 (V1) is nearly 50%; between the OTR and V2R it 
is even lower (40%) (Gimpl and Fahrenholz 2001).  
It should be noted that the expression of the OTRs at the cell membrane and their affinity for 
OT are both regulated. For example, OTRs can be desensitized upon permanent agonist 
stimulation. This process involves multiple mechanisms, and can occur at transcriptional, 
translational or protein levels. The fastest desensitizing mechanism includes phosphorylation 
of the receptor and subsequent ß-arrestin binding. This leads to uncoupling of the GPCR 
from its G-proteins and endocytosis of the receptor. It was found that 60 % of the OTR 
expressed in human kidney fibroblasts (HEK293 cells) is desensitized already after 5-10 min 
of agonist stimulation (Gimpl and Fahrenholz unpublished data). However, due to the 
artificial nature of this system (the OTR has been transfected into the cell), the 
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interpretation of the data has to be taken with care. Moreover, exposure of naturally OTR-
expressing myometrial cells to OT for 20 hours lead only to an almost 10-fold reduction in OT 
binding, with no changes in the OTR protein level. 
Although only one type of OTR exists, it can occur in a high or in a low affinity state. The OTR 
requires at least two essential components for high-affinity binding of OT: divalent cations, 
such as Mg2+ or Mn2+, and cholesterol. These two components determine if the OTR displays 
the high-affinity state with a Kd > 1-50 nM, or the low affinity state with Kd > 100 nM. The 
conversion of the two affinity states is reversible. Cholesterol seems to stabilize the OTR for 
agonists in a high affinity state and acts, like the divalent cations, as an allosteric modulator 
(Gimpl and Fahrenholz 2001). 
OTRs are functionally coupled mostly to Gq/11α class GTP binding proteins that stimulate 
together with Gβγ the activity of phospholipase C (PLC). This leads to the generation of 
inositol-3-phosphate (IP3) and 1,2-diacylglycerate (DAG). IP3 triggers Ca2+-release from 
intracellular stores, whereas DAG stimulates protein kinase C (PKC), which phosphorylates 
downstream targets. The rise in intracellular Ca2+ stimulates the Ca2+/calmodulin system that 
activates the myosin light chain kinase, which in turn leads to smooth muscle contraction, 
e.g. in myometrial cells during labour. However, the OTR does not exclusively bind the Gq-
protein, but also Gi-protein subunits. This implies a differential downstream signaling of the 
activated OTR, since Gi-proteins inhibit adenylyl-cyclase, which reduces cAMP levels (Gimpl 
and Fahrenholz 2001; Busnelli et al. 2012).  
Zhong and co-workers revealed the involvement of the trans-activated epidermal growth 
factor receptor (EGFR) in extracellular signal regulated kinase 1/2 (ERK1/2) activation by the 
myometrial OTR (Zhong et al. 2003). In the PVN, it is this pathway that mediates the 
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anxiolytic activity of OT (Blume et al. 2008). Blockade of the mitogen-activated protein 
(MAP) kinase “MAP ERK kinase 1/2” (MEK1/2) by the inhibitor U0126 attenuated the 
anxiolytic effect of OT in male rats, indicating a central role of MEK1/2 in the mediation of 
the anxiolytic effect of OT.  
In the hippocampus, activation of OTRs lead to Gq/11 – IP3 activation, as well as EGFR- 
ERK1/2-mediated translational induction of the PKC subform PKMζ via the mammalian 
target of Rapamycin (mTOR) complex (Lin et al. 2012). The interplay between these cascades 
triggers long term potentiation (LTP) in the hippocampus, a mechanism also involved in the 
establishment of long-lasting spatial memory (Tomizawa et al. 2003). Blocking the MAPK 
cascade with the MEK inhibitor U0126 inhibited cyclic AMP responsive element binding 
protein (CREB) phosphorylation and subsequent spatial memory formation during 
motherhood (Tomizawa et al. 2003).  
A global knockout of the OTR in male mice results in profound behavioral and physiological 
alterations such as impaired sociability and impaired preference for social novelty, impaired 
cognitive flexibility, increased aggression (Chini et al. 2008; Sala et al. 2011; Sala et al. 2013), 
but also obesity and dysfunction in body temperature when exposed to cold (Nishimori et al. 
2008). In the ventral and dorsal striatum, it also has been reported that OTRs can occur as 
heterodimers coupled to a dopamine D2 receptor, which is thought to produce the 
rewarding effect of a social stimulus during pair bonding (Romero-Fernandez et al. 2013). 
This would increase the rich repertoire of intracellular responses to OTR activation, and 
makes very specific responses to particular stimuli possible. 
In addition, our group found that OTR activation in hypothalamic neurons lead to the 
incorporation of transient receptor potential V2 (TRPV2) channels into the cell membrane 
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and a subsequent influx of Ca2+ from the extracellular space (unpublished data). This influx 
may increase cellular excitability, protein synthesis and neurotransmitter release via several 
Ca2+-dependent signaling cascades. Activation of the TRPV2 channel is upstream of MEK1/2 
phosphorylation, and it has therefore been postulated that blocking TRPV2 channels 
pharmacologically prevents the anxiolytic activity of OT. 
 
2.3 OT and the regulation of stress responses and anxiety 
It has long been established that physical as well as psychological stressors induce OT release 
into the peripheral circulation (Lang et al. 1983; Gibbs 1984). Later studies revealed the 
central release of OT in the hypothalamus and lateral septum upon an emotional stressor, 
which appeared to be independent from peripheral release (Engelmann et al. 1999). 
Furthermore, intra-cerebro-ventricular (icv) administration of a selective OTR antagonist 
(OTA) disinhibited basal and stress-induced (forced swim) HPA axis activity in male and 
female rats (Neumann et al. 2000), as indicated by increased adrenocorticotropic hormone 
(ACTH) and corticosterone release into the blood. Retrodialysis of the OTA in the PVN 
resulted in similar effects in unstressed males and females, locating OTs’ effects on the HPA 
axis to this specific brain region. Interestingly, the expression of the main HPA axis activator, 
CRF, was more enhanced following a physical stressor (4 h of restraint) in the PVN of OT 
gene deficient male mice, when compared to wild type mice suggesting a central inhibitory 
role of OT in the regulation of CRF gene transcription (Nomura et al. 2003) 
In 2004, Windle and co-workers infused OT icv at 1 or 10 ng over a 7-day period via an 
osmotic minipump in female, ovariectomized, estradiol-treated rats and subsequently 
subjected the rats to 30 min restraint stress. This treatment significantly reduced both basal 
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and restraint-induced plasma ACTH and corticosterone levels. CRF mRNA, which was 
measured by in situ hybridization in brain slices collected 210 min after the end of the 
stressor, increased in saline-treated restraint animals, and this increase was absent in OT-
treated stressed rats (Windle et al. 2004). One year later, Ebner et al (2005) found that OT is 
released in the CeA and directs the stress-coping behavior toward a more passive coping 
style, as indicated by an increased floating time in the forced swim test. Blocking the OTR by 
an OTA likewise increased the release of excitatory amino acids (glutamate and aspartate) 
indicating an inhibitory effect of OT in the amygdala (Ebner et al. 2005). This was confirmed 
by a study that revealed that OT excites a population of GABAergic interneurons in the CeA, 
thereby reducing the activity of output neurons in the CeA that control the physiological 
expression of fear (Huber et al. 2005). The relation of axonal OT release in the CeA to fear 
responses has been investigated with the help of a sophisticated optogenetic approach, 
revealing decreased freezing responses in fear-conditioned rats upon blue-light-induced 
release of endogenous OT (Knobloch et al. 2011). 
Besides regulating stress-coping and anxiety in the CeA, OT regulates sexual behavior and 
anxiety in the PVN of males and females. Endogenous, mating-induced release of OT in the 
PVN of male rats was found to be causally involved in mating-induced anxiolysis for up to 4 h 
(Waldherr and Neumann 2007). In addition, exogenous OT infused into the PVN of male rats 
also induces anxiolysis (Blume et al. 2008). 
In contrast to the studies cited above, which suggest that central OT inhibits HPA axis 
activity, peripheral OT might be stimulatory at the level of the pituitary gland. Peripheral OT 
acts as ACTH and corticosterone secretagogue, increasing both basal and stress-induced 
plasma ACTH levels (Gibbs 1984; Petersson et al. 1999) after chronic  (Ondrejcakova et al. 
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2010) or acute (Stachowiak et al. 1995) subcutaneous (s.c.) injection. Similar effects have 
been found in vitro in pituitary explants (Antoni et al. 1983).  
 
2.4 Cross-talk between the OTR and CRFR coupled signaling in the periphery 
What could be the physiological consequences of activation of the OTR and its downstream 
intracellular signaling pathways? One of the targets of the OT system appears to be the 
myometrial CRF system. An interesting study by Grammatopoulos et al (1999) investigated 
the crosstalk between the OTR and the CRF receptor (CRFR) in human myometrium at term 
(Grammatopoulos and Hillhouse 1999). They found that OT reduces CRF binding to the CRFR 
in human myometrial membranes in a time-dependent manner by reducing the affinity of 
the CRF receptor without affecting the number of receptors. The inhibitory effect of OT on 
CRF binding first appeared 15 – 20 min after the onset of OT stimulation. The maximum of 
CRF-binding inhibition (-50%) by OT was reached at 30 min and remained constant for at 
least 2 h. The effect was observed at OT concentrations between 1 – 100 nM OT. Further 
investigations in human myometrial cells suggested a role of PKC in CRF receptor 
desensitization. OTR binding activates the PLC pathway via Gq- proteins, which leads to rapid 
release of Ca2+- ions from intracellular Ca2+ stores. Intracellular Ca2+ activates PKC and 
induces its translocation from the cytosol to the cell-membrane, where it phosphorylates the 
CRF receptor. Phosphorylation of the receptor leads to reduced receptor affinity for its 
agonist. It is interesting to note that this mechanism is only apparent in term, but not pre-
term myometrium membranes. The authors speculate that CRF might influence myometrial 
contractility, and that OT antagonizes the relaxing effect of the activated CRFR. Additionally, 
studies in the pituitary gland describe opposite (i.e. potentiating) effects of PKC on CRF 
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receptor signaling (Cronin et al. 1986). It is not clarified to date how this highly dynamic 
interplay is regulated at the molecular level. It is tempting to speculate, however, that 
different sub-forms of PKC, like the PKMζ (Lin et al. 2012) are responsible for tissue and state 
(pre-term / term) specific effects. 
 
3. Anxiety, stress, and its key regulator CRF 
A physiological state that is intimately connected with anxiety is stress. A fearful stimulus will 
generally not only induce anxiety behavior, but also leads to neural and peripheral 
adaptations that enable an individual to cope with the stimulus; this is known as the stress 
response. Both OT and CRF are involved, and interact in anxiety behavior as well as in the 
stress response. 
 
3.1 Definition of the term “stress” 
It is essential for a living organism to maintain a constant inner environment. This ability to 
create an inner environment, independent from the external environment, was termed 
“homeostasis” by the American physiologist Walter Bradford Cannon (Cannon 1929, 1939). 
Disturbing homeostasis can be perceived as threat, provoking a response from the organism 
to regain a constant inner environment. It was the endocrinologist Hans Selye who termed 
the threat as “stressor” and defined stress as the “nonspecific response of the body to any 
demand placed upon it” (Selye 1936). Later studies revealed that Selye’s definition of stress 
as “nonspecific” was not accurate (Pacak et al. 1998). The stress response is specific to the 
kind of stressor and depends on the organism’s perception of the stressor, and the ability to 
cope with it (Goldstein and Kopin 2007). 
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3.2 Differentiation between physical, psychological, and cellular stress 
For a better understanding of the work presented in this thesis, it is of importance to 
differentiate between physical, psychological and cellular stress, and the processing of each 
at the cellular level. The term “stress” is not always clearly defined in the literature, 
especially at the cellular level, which imposes the need to clarify and define terms that are 
used in this work. Severe physical stressors like cold, blood loss or injuries recruit the 
brainstem and hypothalamic regions, whereas the kind of stress we perceive every day and 
influences the organism’s homeostasis mostly, is of psychological nature, such as social 
embarrassment, examinations, or deadlines (Joels and Baram 2009). This 
physical/psychological stress is processed at a high level of different interacting networks in 
the brain and does normally not include damage to a single neuron. Cellular stress, to the 
contrary, imposes damage to single neurons and, as a consequence of an increasing 
imbalance in central networks, to the whole organism. This kind of stress can be caused by 
UV radiation, hypoxia, or chemical compounds (Chu et al. 2004). Cells respond differentially 
to these different kinds of stressors, however, one universal stress responsive protein is the 
MAPK family member “stress-activated protein kinases” (SAPK) and its most common 
member JNK has been reported to be activated in response to both cellular (e.g. glutamate-
induced excitotoxicity) (Bogoyevitch et al. 2004) and psychological/physical stressors, such 
as forced swim stress in mice (Liu et al. 2004).  
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3.3 Regulation of the CRF neuron 
Under basal conditions the CRF neuron is under inhibitory control by GABAergic 
interneurons, which act via GABA A receptors expressed on hypophyseotropic CRF neurons. 
If a stressor is perceived, depending on the type of stressor (blood loss, immune challenge, 
hypoglycemia), it is directly transmitted to the PVN via the brain stem and spinal cord 
projections to the PVN, or, in case of psychological stressors, integrated via limbic structures, 
such as the CeA, hippocampus, medial prefrontal cortex, or the bed nucleus of the stria 
terminalis (BNST). Additionally, CRF neurons in the BNST are innervated by oxytocinergic 
projections from magnocellular neurons of the PVN, thereby integrating stressors (CRF) and 
stress-protecting actions of OT to fine tune the organism’s stress response. The BNST is a 
central relay station to integrate limbic inputs toward the PVN. The reciprocal innervation of 
CRF and OT neurons between PVN and BNST as described above is thought to be involved in 
balancing stress and affect (Dabrowska et al. 2011). Additionally, CRF neurons are under 
control of somatostatinergic / dopaminergic interneurons in the hypothalamus. Long-day 
photoperiods induce a depressive and anxiety-related behavior in nocturnal rats, via the 
induction of CRF release by somatostatinergic interneurons. These interneurons can switch 
their expression profile and start to synthesize dopamine, which down-regulates CRF release 
and plasma corticosteroids in response to a short-day photoperiod (prolonged active phase) 
(Dulcis et al. 2013). 
Other neurotransmitters, such as dopamine, histamine, and acetylcholine are likely to 
modulate CRF neurons indirectly by modulating the activity of afferent neurons (Lee et al. 
2008), for review see (Aguilera and Liu 2011)). Influences from the periphery are mediated 
by hormones such as angiotensin II, prolactin and leptin. Since these peptides cannot cross 
the blood-brain-barrier, specialized organs (circumventricular organs) receive these 
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hormonal signals and transmit them to central nuclei. Circumventricular organs, such as the 
subfornical organ, express the angiotensin II receptor to recognize peripherally released 
angiotensin II, which is the end product of the renin-angiotensin system, and transmit this 
stress-induced signal directly to the PVN. Another circumventricular organ, the choroid 
plexus, is involved in the uptake of prolactin, which results in hypo-responsiveness of the 
HPA axis during lactation (Blume et al. 2009). 
 
3.4 Transcriptional regulation of the CRF gene 
There is one gene encoding for CRF, which is located on the long arm of chromosome 8, with 
one promoter region, one intron (800 bp) and two exons (582 bp). The gene codes for the 
inactive pro-hormone. The pro-hormone is transcribed, translated, and processed into the 
active CRF peptide. There is a 97% homology of the promoter region between humans, mice, 
rats, and sheep, which suggests that signals leading to CRF gene transcription are highly 
conserved among mammals (King and Nicholson 2007). This allows for comparisons between 
animal and human hypothalamic response to stress. The human CRF gene promoter contains 
several response elements (RE) that, upon binding of their cognate factors, either activate or 
repress transcription of the CRF gene. There are three elements (metal-responsive 
transcription factor 1 RE, hybrid steroid RE, ecdysone RE) which activate gene transcription 
by inhibiting two repressive elements (Ying Yang RE, negative glucocorticoid RE (nGRE)). If 
these repressive elements are inhibited, the cyclic AMP RE (CRE) is free to bind CREB and its 
co-activators. There are also two canonical TATA-Box elements present in the CRF gene, only 
one of which seems to be involved in transcriptional regulation, the second one is thought to 
be silent (King and Nicholson 2007). The best studied inhibitory mechanism of CRF 
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transcription is the negative feedback regulation by glucocorticoids (GC). The activated HPA 
axis leads to the production and release of GCs, which cross the blood brain barrier to bind 
the GC receptor (GR) in the brain (hippocampus, PVN). This complex translocates to the 
nucleus and binds the nGRE in the CRF promoter. This inhibits the binding of the 
transcriptional machinery to the CRE region, thereby reducing CRF gene transcription 
(Jeanneteau et al. 2012). 
Recent studies showed that the transcription of the CRF gene is also under the control of the 
CREB co-activator CRTC2. The molecular machinery employed is described in more detail in 
the CRTC section below. In brief, in vitro and in vivo studies revealed that CREB 
phosphorylation is essential but not sufficient for forskolin (FSK) or restraint stress-induced 
CRF gene transcription. The activation, i.e. dephosphorylation of the co-activator CRTC2 and 
its subsequent translocation to the nucleus is essential for a full transcriptional response (Liu 
et al. 2008; Liu et al. 2011).  
 
3.5 Peripheral effects of CRF 
CRF is the central regulator of the HPA axis, which mediates the organism´s response to a 
perceived stressor. The main regulatory brain region of the HPA axis is the hypothalamic 
PVN. The PVN contains the highest concentration of CRF neurons in the brain. It lies adjacent 
to the 3rd ventricle and consists of large magnocellular and smaller parvocellular neurons. 
The medial-dorsal parvocellular CRF neurons release CRF via the external zone of the median 
eminence into the hypophyseal portal blood capillaries to the adenohypophysis. These CRF-
neurons co-express and co-release AVP together with CRF in response to a variety of 
psychological and physiological stressors into the portal circulation (Aguilera 1994, 1998; 
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Aguilera and Liu 2011). This increase serves as a trigger for the release of effector-hormones, 
such as ACTH, from the adenohypophysis into the blood stream. Interestingly, the circadian 
activation of the CRF neuron is delayed to the daily changes in circulating ACTH and 
corticosterone in rats (Watts et al. 2004), suggesting that HPA axis activity is driven by the 
release of CRF pool contents, followed by the transcriptional replenishment of the pools. 
During acute stress, CRF and AVP are rapidly released into the portal blood system to induce 
the full ACTH response. This release is followed by an increase of CRF gene transcription, and 
later on, AVP gene transcription (Herman et al. 1992; Ma et al. 1997). However, CRF is 
considered to be largely responsible for HPA axis activation, while AVP was reported not to 
be essential, but potentiating the organism’s response to a stressor (Aguilera et al. 2008). 
Interestingly, other researchers favor a model of synergistic actions of AVP and CRF, instead 
of additive effects, to fully induce the stress response (Chen et al. 2008; Spiga et al. 2009). 
The binding of CRF to the CRF receptor 1 (CRFR1) expressed by the corticotrophe cells in the 
pituitary gland, activates adenylate cyclase, thus increasing cAMP levels. cAMP, in turn, 
activates protein kinase A (PKA), which translocates to the nucleus and up-regulates the 
expression of pro-opiomelanocortin (POMC). POMC can be cleaved in several active 
peptides, one of which is ACTH. The release of ACTH into the circulation will induce the 
synthesis and secretion of glucocorticoids (GC) upon binding to the melanocortin-2-receptor 
(Mc2r) expressed in the zona fasciculata of the adrenal cortex. The synthesis of GCs is rate-
limited by the availability of the steroidogenic acute regulatory protein (StAR). The StAR 
enzyme stimulates the initial mitochondrial metabolism of cholesterol to pregnenolone by 
enhancing cholesterol transfer from the outer membrane to cytochrome P450 11A1 
(P450scc) in the inner membrane (Stocco et al. 2001; Stocco et al. 2001; Jefcoate 2002). To 
initiate transcription of the StAR enzyme, the cooperative actions of multiple transcription 
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factors, including CREB (Clem et al. 2005) and its co-activator CRTC2 (Takemori et al. 2007; 
Liu et al. 2012), CCAAT enhancer- binding protein (C/EBP β), steroidogenic factor 1 (SF-1) 
(Manna et al. 2003; Manna et al. 2003) and GATA4 (Silverman et al. 2006) are required. The 
proximal region of the mouse StAR promoter contains three canonical 5’ CRE half-sites 
(TGAC) that are bound by the activated CREB/ATF-1/CBP-p300/CRTC2 complex (Takemori et 
al. 2007; Liu et al. 2012). 
 
3.6 Central effects of CRF 
CRF plays an important role in the regulation of the HPA axis, but recent findings have shown 
that production and central release of CRF during stress influences neuronal structure and 
the functionality of the hippocampus and other brain regions. In fact, whereas mild or short-
lasting stress enhances hippocampal function by augmenting synaptic plasticity, chronic 
stress impairs learning and memory by retraction of pyramidal cell dendrites, likely to be 
caused by the chronic presence of stress-induced CRF. The integrity of dendrites is only 
guaranteed if excitatory synapses are present on specialized structures called dendritic 
spines. The picture below represents an organotypic slice taken from a murine hippocampus 
and incubated with 100 nM CRF for 2 weeks. This treatment induces a significant loss of 
dendritic branching (Maras and Baram 2012). 
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Figure 2 100 nM of CRF applied onto hippocampal organotypic slice cultures 
reduced dendritic complexity. Picture taken from (Maras and Baram 2012) 
 
The number and functionality of dendritic spines is highly dynamic and can be influenced by 
neurotransmitters, hormones, and growth factors, which are in turn governed by 
environmental signals like stress (Maras and Baram 2012). Chronic stress, for instance, tends 
not only to cause dendritic retraction, but also inhibits neurogenesis and reduces survival of 
hippocampal neurons in a sex-dependent manner (Hillerer et al. 2013). In addition, acute 
(i.e. 30 min) restraint stress with subsequent intermittent tail stimulations increase spine 
densities in the hippocampal CA1 area of male rats (Shors 2009), while the same stimulus 
causes a decrease in hippocampal spine density in females. These sex-dependent stress-
induced effects are also observed in the medial prefrontal cortex (mPFC), where stress 
decreases dendritic branching and length of pyramidal neurons in males, but increases these 
parameters in females (Garrett and Wellman 2009; Shansky and Morrison 2009). Stress-
induced remodeling of layer V neurons in the mPFC has an impact on projections to 
subcortical regions like the BNST and amygdala, both being related to regulation of adaptive 
and maladaptive responses to stress (Gabbott et al. 2005; Conrad et al. 2011; Radley and 
Sawchenko 2011). The amygdala is most often linked to anxiety. However, recent human 
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and rodent studies revealed that the amygdala is more relevant to fear or short term anxiety 
responses, whereas the BNST is more involved in sustained anxiety (Davis et al. 2010; Leuner 
and Shors 2013). Intriguingly, the BNST is reciprocally connected with the PVN, with 
oxytocinergic projections toward the BNST, and CRF fibers originating in the BNST projecting 
toward the PVN (Dabrowska et al. 2013). This anatomical arrangement represents a direct 
morphological link of the CRF system with the oxytocinergic system. Considering the sex 
dependency of the stress response, reproduction-induced neuroplasticity (likely to be 
related to the oxytocinergic system), and the common brain regions these systems share, it 
is possible that OT is a sex-specific regulator of the CRF-driven stress response with major 
impact on the morphology of neurons in stress-related brain regions. It is tempting to 
speculate that the release of OT during stress serves as a modulator of CRF expression in a 
time-dependent manner, to prevent neuronal damage by large amounts of stress-induced 
CRF (see Results). 
 
4. OTR-coupled signaling cascades and the regulation of CRF gene transcription 
CREB and CRTC signaling is one example of how intracellular effectors of receptor activation 
can modulate gene expression. Today, literally hundreds if not thousands of such factors 
have been characterized, and some of them will be highlighted here as they might be 
involved in OT-mediated signaling and social behavior, or the control of CRF gene expression 
and stress responses. 
Between 1994 and 2001, substantial progress has been made in the understanding of the 
mammalian MAP kinases. The first MAP kinase to be discovered was the extracellular signal 
regulated kinase 1 (ERK1), which is encoded by the MAPK3 gene. The closely related ERK2 
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(encoded by the MAPK1 gene) was identified in the same year. In the following years a 
plethora of mammalian MAPKs were identified, revealing an evolutionary highly conserved, 
and ubiquitously expressed enzymatic machinery in all eukaryotic cells. Mitogens, the first 
identified stimulators of MAPK signaling gave the protein family its name, although a diverse 
set of extracellular stimuli can activate MAPKs. Stimuli like hormones, growth factors, 
cytokines, GPCR regulated agents, transforming growth factor (TGF)-ß-related agents, and 
environmental stresses. As diverse as the stimuli are the effects on the cell physiology. 
MAPKs are involved in the regulation of gene transcription, protein biosynthesis, cell cycle 
control, apoptosis, and cell differentiation (Kyriakis and Avruch 2012). 
The substantial core of MAPK signaling is a three-tiered module, in which activating signals 
are passed on as phosphorylation of specific motifs (Thr-X-Tyr) in the kinase subdomain VIII 
activation loop of the MAPK. The upstream kinases of MAPK are named dual specificity 
MAPK Kinase, MAP2K, MEK, or MKKs. These kinases are activated by Serine/Threonine 
(Ser/Thr) phosphorylation by a wide variety of MAPK kinase kinases (MAP3K) (Kyriakis and 
Avruch 2012). 
MAPKs have remarkable substrate specificity. They phosphorylate Ser/Thr residues only if 
they are followed by a proline, and the presence of a MAPK docking site. Despite the high 
selectivity of the individual elements of the core signaling module, MAPK show promiscuous 
functions in related signaling cascades and are often regulated by a variety of extracellular 
signals. The question arose, how MAPKs maintain their signal/substrate specificity if the 
components are directed by proline and MAPK docking sites on the one hand, but can 
couple to multiple substrates on the other hand. The answer to this question lies in the 
function of scaffolding proteins, which sequester the elements of the cascade, bring them in 
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close physical contact, and thereby maintain signal specificity, and subcellular localization 
(Kyriakis and Avruch 2012; Roskoski 2012). 
 
4.1 The ERK cascade 
The highest upstream activators of the ERK cascade are receptor tyrosine kinases (RTKs) like 
the EGFR, which recruit the membrane associated proto-oncoprotein GTPase Rat sarcoma 
(Ras) via several possible intermediate signaling proteins (see Figure 3), depending on the 
subcellular localization of the cascade. Ras in turn phosphorylates the family of Raf MAP3Ks, 
such as Raf-1 (also known as c-Raf), A-Raf, and B-Raf. Raf-1 was first identified 1983 in 
murine retrovirus infected fibroblast cells, and named Virus-induced Rapidly Accelerated 
Fibrosarcoma (V-Raf). Later studies revealed the ubiquitous expression in all eukaryotic cells, 
so the gene’s name was changed to cellular-Raf (c-Raf) (Osborne et al. 2011). C-Raf is the 
gatekeeper of the entire ERK cascade and therefore regulated at multiple steps. It contains 
an auto-inhibitory region, which physically blocks the kinase domain of the protein. Only 
GTP-bound Ras can compete with the auto-inhibitory block, leading to a conformational 
change and the relief of the kinase domain. Scaffolding proteins such as kinase suppressor of 
Ras (KSR) or 14-3-3 are either inhibitors or activators of Ras signaling, depending on their 
phosphorylation status. Non-phosphorylated 14-3-3 does not bind Ras, and this in turn is 
regulated by the TGF beta activated kinase 1 (TAK1) or the Protein phosphatase 1 (PP1) / 
Protein Phosphatase 2A (PP2A). Once c-Raf is in an active state, with its auto-inhibitory site 
deactivated, 14-3-3 can act as an activating scaffolding protein, by bringing Ras and its 
substrates (e.g. MEK1/2, BAD, adenylate cyclase and others) in close proximity (Osborne et 
al. 2011; Kyriakis and Avruch 2012). Interestingly 14-3-3 is also a scaffolding protein for 
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CRTCs, representing a direct spatial link between the MAPK cascade and the CRTCs (see 
CRTC section of the Introduction). MEK1 (also known as MAP2K1, MAPKK1, MKK1) and MEK2 
are the direct downstream substrates of c-Raf. The protein MEK contains a phospho-domain 
in its C-terminus, and a trifunctional N-terminal sequence with an inhibitory segment, a 
nuclear export sequence, and an ERK binding site (Fischmann et al. 2009). Contrary to the 
complexity observed in c-Raf activation, MEK and ERK are simply activated by dual 
phosphorylation of their respective activating residues (Ser218 and Ser222 for MEK1; Ser222 
and Ser226 for MEK2; Thr185 and Tyr 187 for ERK2 or Thr203, Tyr205 for ERK1). 
Interestingly, phosphorylation of Ser212 in MEK1 decreases the kinase activity of MEK in 
vivo, without interfering with the ERK2 binding or other activating phosphorylated residues 
(Gopalbhai et al. 2003). Other residues have been shown to be inhibitory as well, such as 
T286, which is phosphorylated by cyclin dependent kinase 5 (Cdk5). This kinase has several 
functions in cell proliferation, brain development and synaptic vesicle exocytosis. 
Furthermore, T292 in MEK1 is a substrate of ERK, which implies a negative feedback loop to 
reduce ERK activation by direct inhibition of MEK by ERK. 
For many years, ERK was the only known substrate of MEK, only recently (2006-2010) new 
MEK targets were identified, such as PPARγ, MyoD, PI3K, or LIMKinase 1 in a variety of 
tissues (Brandt et al.; Jo et al.; Klemke et al.; Burgermeister et al. 2007). All these recent 
findings imply the possibility of MEK activation without subsequent ERK phosphorylation. 
The distribution of the MAPK cascade in the rat brain has been studied intensively. MEK1 has 
been shown to be expressed in many brain regions, including the cortex, hippocampus, 
amygdala, bed nucleus of the stria terminals (BNST), lateral septum, hypothalamus (most 
notably in the PVN), cerebellum, and the brainstem (Flood et al. 1998).  
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Figure 3   Receptor tyrosine kinase (RTK) to ERK signaling: Ras and ERK activation at various intracellular 
compartments. At the plasma membrane, activated RTKs promote Ras activation through the recruitment of 
growth factor receptor bound protein 2 / Son of sevenless (Grb2/Sos) complexes. Kinase suppressor of Ras 
(KSR) is an ERK scaffold that facilitates Ras dependent ERK cascade activation at the plasma membrane, 
whereas Paxillin directs ERK activation at focal adhesions. Active signaling complexes containing internalized 
receptors, Grb2/Sos and Ras are also found on endosomes. MEK partner-1 (MP1) is an MEK1/ERK1- specific 
scaffold that localizes to late endosomes through an interaction with the adaptor protein p14. Activated RTKs 
can also direct the activation of Golgi-associated Ras through a signaling route involving sarcoma (Src), 
Phospho-lipase-C (PLC)-γ and Ras-general receptor of phosphoinositides-1 (GRP1). Similar expression to fgf 
genes (Sef) is a Golgi-localized scaffold that recruits activated MEK and promotes ERK activation. Active ERK is 
retained on the Sef/MEK complex and confined to cytosolic substrates. The tyrosine phosphatase Src homology 
phosphatase-2 (Shp-2) is another effector of RTKs that positively regulates Ras signaling by antagonizing the 
ability of negative regulators, such as cellular-Src kinase (CSK), RasGAP and Sprouty, to access and 
downregulate critical enzymes involved in Ras activation. Picture taken from (McKay and Morrison 2007) 
 
ERK1 and ERK2, two of the direct downstream targets of MEK1/2, transduce extracellular 
signals to the nucleus to regulate processes as diverse as proliferation, differentiation, 
apoptosis, and synaptic plasticity (Zhuang and Schnellmann 2006). When dephosphorylated, 
ERKs are basically incapable of catalyzing the transfer of phospho-groups (20 to 30 pmol 
min−1 mg−1), mainly because interactions with cognate substrates are hindered by the 
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structural configuration of the activation loop of the kinase. MEK-mediated activation 
induces conformational changes that enhance the catalytic activities of the ERKs by about 5 
orders of magnitude (5 μmol min−1 mg−1) (Chang and Karin 2001; Kyriakis and Avruch 2012). 
After being dually-phosphorylated, ERK1 dimerizes, which enables it to generate peak kinase 
activity, while a dual-phosphorylated monomer ERK1 is thought to maintain basal activity 
(Philipova and Whitaker 2005). However the nuclear translocation seems to be dimerization-
independent, but is controlled by the rate of phosphorylation (Lidke et al.). These facts lead 
to the hypothesis that dual-phosphorylated ERK dimers, with the help of cytosolic 
scaffolding proteins that act as assembling platforms, target cytosolic proteins, and dual-
phosphorylated monomers, that are released from these scaffolds, have nuclear targets. The 
release of ERK from its scaffolding proteins and the redistribution over cellular 
compartments, including the nucleus, cytosol, plasma membrane, intracellular vesicles, 
mitochondria and cytoskeletal components, enables contact with and subsequent 
phosphorylation of nearly 200 target proteins (Whitehurst et al. 2002; Yoon and Seger 
2006). While there is evidence for a carrier-independent mechanism of nuclear entry of 
ERK2 (Whitehurst et al. 2002) by direct binding of ERK2 to a nuclear pore complex 
(Matsubayashi et al. 2001), the nuclear import of ERK1 is poorly studied. However, ERK1 
seems to shuttle between cytosol and nucleus at a much slower rate than ERK2, and this 
difference is caused by differences in an N-terminal domain of ERK1. This N-terminal domain 
forms the main difference between ERK1 and ERK2; moreover, they share 85% of amino-acid 
sequence identity, and all other known functional domains (Marchi et al. 2008).  
This shuttling of ERK is independent of its phosphorylation status, which might point toward 
a kinase-independent function of ERK in the nucleus. Indeed, recent studies discovered new 
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targets of ERK that are not necessarily modified by phosphorylation. ERK is involved in 
important cellular processes, such as chromatin remodeling, DNA transcription, and cell 
cycle regulation, acting independently of their kinase activities. In more detail, one example 
concerns the posttranslational modification of dual specificity phosphatase-6 (DUSP6) also 
known as MAPK phosphatase-3 (MKP-3), whose catalytic activity is increased 30 fold upon 
binding to ERK2. DUSPs specifically target MAPKs to fine tune their activity by 
dephosphorylation. Most DUSPs are encoded by inducible genes, the transcription of which 
is mainly regulated by MAPK themselves, or glucocorticoids. A second level of regulation is 
posttranslational modification of the phosphatase by its target. The binding of ERK2 to 
DUSP6 is sufficient to induce an allosteric conformational change that leads to the 
reorganization of the consensus acidic residue in the phosphatase, which results in 
enhanced catalytic activity. The specific recognition of ERK2 by MKP-3 is mediated by a 
conserved motif within the N terminal region of DUSP6 (Camps et al. 1998). Another non-
canonical target that does not require kinase activity of ERK is poly (ADP-ribose) polymerase 
1 (PARP-1), which is bound by phosphorylated ERK2, and activated without phospho-transfer 
activity. PARP-1 subsequently binds the transcription factor Elk-1, thus enhancing its 
transcriptional activity of genes such as c-fos. Acetylation of the core histones H3 and H4 is 
also enhanced in response to ERK2-mediated activation of PARP-1 (Cohen-Armon et al. 
2007). 
ERK2 is not only a signaling mediator between proteins, but also a DNA binding factor. High-
throughput screening of the human protein-DNA interactome in HeLa cells identified ERK2 
as a transcriptional repressor of interferon-γ(IFN-γ)–induced genes (Hu et al. 2009). Analysis 
of 82 genes that were increased in expression in response to knockdown of ERK2 revealed 
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G/CAAAG/C as the consensus sequence for the binding of ERK2. Within promoters, these 
ERK2-binding sites appear at around −90 base pairs, a typical distribution for many 
transcriptional regulators (Roy et al. 2000). 
Besides these recently discovered non-canonical targets, ERK has its “normal” downstream 
signaling cascade substrates. The first identified substrate, which is exclusively 
phosphorylated by ERK1/2 and not by JNK or p38 (see p38 and JNK paragraph in the 
Introduction) was the ribosomal S6 Kinase (Rsk). This kinase derives its name from its kinase 
activity on the small ribosomal protein S6. However it does not represent the major kinase 
of the S6 protein, which is the S6K. Rsk is activated by ERK1/2, which phosphorylates the C-
terminal catalytic domain. The activated catalytic domain auto-phosphorylates Rsk at 
Ser380, which provides a docking site for 3-phosphoinositide-dependent-kinase 1 (PDK1), 
which finally leads to full activation by phosphorylating Ser222 in the activation loop of the 
N-terminal domain (for review (Kyriakis and Avruch 2012). One factor that leads to MEK, ERK 
and Rsk activation in a hypothalamic neuronal cell line is AVP (Chen et al. 2009).  
The shuttling of ERK and RSK is, among others, regulated by phosphoprotein enriched in 
Astrocytes-15 (PEA-15- or PED), a small protein (15 kDa) with an N-terminal death effector 
domain and an irregular C-terminal tail. The name suggests that it is expressed solely in 
astrocytes, but later studies revealed its ubiquitous expression in all neural cell types with a 
highly conserved structure among mammals (Araujo et al. 1993). The activation of PEA-15 
and its control over ERK is tightly regulated. Under resting conditions, ERK is bound to PEA-
15 in the cytosol. Upon EGFR-induced Ca2+ influx, activated Ca2+-calmodulin dependent 
kinase II (CaMKII) phosphorylates the Ser116 residue of PEA-15, which allows the PKC 
mediated phosphorylation of Ser104. Dual-phosphorylation of PEA-15 releases ERK from 
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PEA-15 and allows its shuttling to the nucleus. The phosphorylation status of ERK is not 
altered by PEA-15 binding, so that PEA-15 restricts ERK activity to cytosolic targets, such as 
RSK or stathmins (Renault et al. 2003) (for the role of stathmins in behavior see Introduction 
JNK paragraph). The effects of PEA-15 on RSK are bi-functional. First, PEA-15 blocks nuclear 
accumulation of RSK after epidermal growth factor stimulation. Second, PEA-15 inhibits RSK2 
kinase activity by 50 %. RSK1 is not bound by PEA-15 (Vaidyanathan and Ramos 2003; 
Vaidyanathan et al. 2007). The central importance of PEA-15 activity on MAPK cascades has 
been demonstrated by a PEA-15 knockout mouse line, which displayed altered CREB and c-
fos mediated gene transcription activity. This results in a heightened stress reactivity and 
anxiety and impairment of spatial memory (Ramos et al. 2009). 
 
Figure 4 Depiction of the MAPK pathway and its inhibitory scaffolding protein PEA-15. Taken from (Kinbara et 
al. 2003) 
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Furthermore, the MAPK-interacting kinases (MNKs) are downstream ERK 1/2 targets. MNKs 
are involved in translational regulation, which occurs at the 5’ methylguanosine cap 
structure. The eukaryotic initiation factor (eIF)-4E tethers mRNA onto a scaffolding protein, 
and with the help of other co-factors, unwinds the secondary structure of the mRNA, which 
allows the ribosomal complex to scan the mRNA. The exact role of eIF-4E phosphorylation by 
MNKs in transcriptional regulation is still under debate. However, directly related to eIF-4E 
phosphorylation is another interesting translational repressor binding protein (4E-BP1), 
which interrupts the eIF-4E interaction with its co-factors, but dissociates from the 
translational complex upon phosphorylation induced by the mammalian target of rapamycin 
(mTOR) (Sonenberg and Gingras 1998). Studies have shown a co-localization of activated (i.e. 
phosphorylated) mTOR and oxytocinergic neurons of the PVN (Lembke et al.) in the context 
of energy balance in fasted rats. mTOR is a protein central to the regulation of protein 
translation, and has shown to be involved in mediating the fast antidepressant effects of 
NMDA antagonists by synapse formation (Li et al.). The central role of mTOR in the 
regulation of mRNA translation, its regulation by MAP Kinases (see Figure 5) and its co-
localization with OT in the PVN, identifies the possibility for a role in mediating the effects of 
OT on protein synthesis (Devost et al. 2008), and hence sustained anxiolytic effects. 
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Figure 5   Schematic representation of the molecular mechanisms employed by the Ras/MAPK pathway 
to regulate mTORC1 signaling. Activation of the Ras/MAPK pathway stimulates mTORC1 activity through the 
coordinated action of the kinases ERK1/2 and Rsk on the tuberous sclerosis (TSC) protein complex upstream 
mTORC1, and on Raptor, an important partner of mTOR within mTORC1. Taken from (Carriere et al. 2011) 
 
Another family of ERK substrates are the Mitogen- and Stress-activated Protein Kinases 
(MSKs). MSKs can be phosphorylated by ERK1/2 and p38 (for p38 see respective chapter in 
Introduction), and are therefore mediators of many physiological and pathological stimuli. 
Their most acknowledged activity lies in the phosphorylation of CREB and nuclear factor κB 
(NF- κB).  
Recent studies revealed an additional role for MSKs in histone phosphorylation, which leads, 
just like histone acetylation, to chromatin relaxation and facilitated binding of proteins 
 
39 
 
involved in transcription. It has been reported that MSKs were necessary for EGF-induced 
Histone 3 (H3) Ser10 phosphorylation of the cellular-Finkel-Biskis-Jinkins murine 
osteosarcoma virus homolog (c-Fos) - promoter (Duncan et al. 2006). MSKs are 
predominantly found in the nucleus and can partly be relocated to the cytosol upon GC 
signaling. It is therefore suggested that MSK1 contributes to the anti-inflammatory actions of 
GCs, by impairing transcription of genes related to inflammatory processes by nuclear export 
of MSKs. Gene transcription is regulated by transcription factors, of which CREB is the most 
studied one. The influence of MSKs on CREB and its result on gene transcription will be 
described in the CREB paragraph of the Introduction and in the Results section. 
 
4.2 P38 and JNK 
P38α was the first isolated isoform of the stress-, inflammatory cytokines, and endotoxin-
induced MAPK p38. There are four p38 genes (p38α to p38δ), however, p38 is a MAPK often 
overseen and poorly studied. There is evidence, that p38 disrupts BDNF-induced TrkB 
signaling, thereby inhibiting long term potentiation (LTP) (Tong et al.), but the effects of p38 
are often studied in relation with other members of the MAPK family, because exclusive p38 
activation is rarely seen (Chang 2012). The downstream targets of p38 are mainly MNK1/2, 
which regulates the activity of eIF-4E, and MSK1/2, which is the main kinase of the 
transcription factor CREB (see CREB paragraph in the Introduction). 
The dominant stress-induced MAPK is the stress activated protein kinase (SAPK) or c-Jun N-
terminal kinase (JNK). It is named after its substrate, the transcription factor c-Jun, short for 
cellular–ju nana, which is Japanese for 17 and refers to the avian sarcoma virus 17, from 
which the protein has been originally isolated. C-Jun recognizes and binds to the enhancer 
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heptamer motif 5'-TGA(C/G)TCA-3'. It activates gene expression through direct interaction 
with enhancers, and has structural similarities with the activating protein 1 (AP1) (Bohmann 
et al. 1987). There are three main isoforms, JNK1, JNK2, and JNK3, encoded by the MAPK 8, 
9, and 10 genes, respectively. Each JNK isoform contains the typical MAPK Thr-X-Tyr 
phospho-acceptor loop in its kinase subdomain VIII. The JNK specific phosphorylation sites 
are Thr183 and Tyr185 (for review (Kyriakis and Avruch 2012). The JNK1 and JNK2 isoforms 
are ubiquitously expressed, while JNK3 is almost exclusively found in the brain and testis. 
Upstream of JNK are the MAP2Ks MKK4 and MKK7. MKK4 is localized in the cortex, 
hippocampus, amygdala, BNST, thalamus, hypothalamus, cerebellum, and brainstem of the 
adult rat central nervous system (Flood et al. 1998), and was shown to co-activate p38, while 
MKK7 is a specific upstream kinase of JNK, expressed at a much lower level, especially in the 
liver (Nishina et al. 1999). However, whereas MKK4 is present in cell body, dendrites and 
axons of neurons, MKK7 is exclusively detected in the nucleus. JNK is phosphorylated by 
MKK4/7 upon stressful stimuli in an isoform-dependent manner. It has been shown that 
JNK2/3 are strongly activated by trophic withdrawal, while JNK1 phosphorylation remained 
constant (Coffey et al. 2002). Constant JNK1 activity is related to the stability of microtubule 
associated protein, which influences dendritic and axonal outgrowth. It is therefore highly 
possible that MKK4 plays a prominent role in regulating the establishment of functional 
neural circuits in the brain via JNK1 (for review see (Wang et al. 2007). The interplay 
between MKK7 and JNK can be disrupted by activated (hormone-bound) GR. It was shown 
before that GC can repress the activation of the transcription factor activator protein 1 (AP-
1), and this repression is likely mediated via physical interaction with JNK through a 
hormone-regulated docking site located in the ligand-binding domain of the GR. Thus, stress-
induced GCs can interrupt JNK-mediated stabilization of microtubules, which is a necessary 
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prerequisite for axonal branching and therefore neuronal plasticity and memory formation. 
In fact, GCs are not the only regulators to induce dendritic and axonal outgrowth via JNK. 
Jeanneteau et al could show that BDNF-induced MAPK phosphatase-1 (MKP-1; also known 
as dual specificity phosphatase-1 (DUSP-1)) activation (via TrkB-ERK signaling) leads to JNK 
dephosphorylation, microtubule destabilization (via stathmin dephosphorylation), and 
subsequent axonal branching (Jeanneteau et al.). Stathmins, the downstream effectors of 
JNK, have been shown to be involved in the establishment of social and parental behavior in 
the basolateral amygdala of female rats (Martel et al. 2008). This pathway shows one 
possibility of how intracellular cascades can, by influencing cytosolic target proteins, change 
neuronal circuits and thereby the behavior of an animal. 
 
4.3 The transcription factor CREB 
Cyclic AMP responsive element binding protein (CREB) is a transcription factor that 
promotes genome-wide changes in gene expression if activated by hormonal (GPCR) stimuli, 
Ca2+-influx, growth factors, osmotic stress and ultraviolet irradiation. CREB-regulated gene 
expression, such as that of c-fos, BDNF, neuronal nitric oxide synthase (nNOS), somatostatin, 
peroxisome proliferator-activated receptor γ (PPARγ) co-activator 1α (PGC1α), B cell 
lymphoma 2 (Bcl-2), the StAR enzyme and CRF (Yamamori et al. 2004; Sasaki et al. 2011), is 
the molecular basis of adaptive behavioral changes that occur in response to a changing 
environment, learning and memory in mature organisms, as well as cell proliferation and 
differentiation in a range of cell types of developing vertebrates (Bonni et al. 1999; Riccio et 
al. 1999; Walton et al. 1999). 
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CREB was first discovered 1987 as a gene transcription activating, DNA binding protein in the 
promoter sequence of the somatostatin gene (Montminy and Bilezikjian 1987). The binding 
region is named “cyclic AMP responsive element” and concerns typically either palindromic 
(TGACGTCA) or half site (TGACG or CGTCA) sequences. A small number of variants have been 
described since then. There are about 750.000 palindromic or half sites in the human 
genome, but the large majority is silenced by disruptive cytosine methylation within the CRE. 
Non-methylated CREs in the promoter of active genes appear in about one quarter of the 
human genome (~ 5000 genes). CREB typically contains an amino-terminal transactivation 
domain (TAD) and a C-terminal basic Leucine zipper (bZIP) DNA binding and dimerization 
domain. Upon phosphorylation, CREB forms either homodimers with itself, or heterodimers 
with the other members of the CREB family, including ATF and CREM. The TAD consists of a 
central kinase inducible domain (KID) and a cAMP responsive glutamine-rich domain (Q2 
domain), which enhances transcription by interacting with the “TATA-box binding protein 
associated factor 4” (TAF4), a component of the basal transcription factor IID (TFIID). In 
contrast to the Q2 domain, the KID domain is activated in response to cAMP and Ca2+ 
through a phosphorylation-dependent mechanism. In general, binding of a ligand to a GPCR 
activates the stimulatory subunits of the G-protein (α, β, γ), which in turn activate the 
membrane bound adenylate-cyclase (AC) to synthesize cAMP from ATP. cAMP binds to the 2 
regulatory subunits of the PKA, thereby releasing the catalytic subunits of PKA. The catalytic 
subunits translocate to the nucleus by passive diffusion and phosphorylate nuclear CREB at 
Ser133 in its KID domain. Phosphorylation at Ser133 promotes association of the KID with 
the KIX domain of the co-factor CBP/p300, which enhances CREB target gene expression by 
acetylating histones, and recruiting RNA polymerase II complexes. 
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In neurons, trans-synaptic release of glutamate triggers Ca2+-influx through N-methyl-D-
aspartate (NMDA) receptors and L-type voltage sensitive Ca2+ channels (L-VSCC). This 
elevated Ca2+-level is responsible for activating nuclear CaMKIV, which phosphorylates CREB 
at Ser133 at an early phase, but also, by activating the MAPK pathway, to prolong Ser133 
phosphorylation via RSK (Wu et al. 2001). 
The estimated number of CREB molecules per cell (40.000) (Hagiwara et al. 1993) is in far 
excess of the number of putative CREB target genes (5000) (Zhang et al. 2005). Additionally, 
many different stimuli lead to CREB Ser133 phosphorylation. To maintain stimulus / 
substrate specificity, a set of co-activators and/or stimulus-specific CREB modulations that 
direct activated CREB molecules to the promoter of specific target genes has been 
hypothesized. Indeed, the group of Greenberg discovered a mechanism, how a specific 
stimulus (Ca2+-influx) can activate a subset of CREB regulated target genes by Ca2+-
dependent phosphorylation of the Ser142 and Ser143 in the KID domain of CREB by CaMKII. 
Triple phosphorylation of CREB (Ser133, Ser142, and Ser143) induces selective Ca2+-
dependent gene transcription, different from that of monophosphorylated CREB at Ser133, 
by disrupting the binding of CBP to CREB via the KIX (CBP) - KID (CREB) domains, which 
allows gene transcription only of genes that are not dependent on the presence of CBP. 
Interestingly, phosphorylation of the Ca2+-dependent Ser142/143 seems to follow slower 
kinetics compared to the rapid Ser133 phosphorylation (see Figure 6 and (Kornhauser et al. 
2002)), a mechanism that might prolong CREB activation independent of CREB Ser133 
phosphorylation.  
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Figure 6  Distinct kinetics of depolarization-induced phosphorylation of CREB at Ser133, Ser142, and 
Ser142/Ser143. Values within each experiment were normalized to the highest value (maximum level = one), 
and mean values across experiments are plotted for anti-P133 (open circles), anti-P142 (closed circles), and 
anti-P142/143 (closed squares) signals. Each data point represents at least three independent experiments. 
adapted from (Kornhauser et al. 2002) 
 
 
The physiological importance of the MAPK mediated CREB phosphorylation for spatial 
memory was revealed by Tomizawa and co-workers (Tomizawa et al. 2003) by icv injection 
of OT in virgin mice, which improved spatial learning and enhanced CREB phosphorylation by 
MAPK (MAPK inhibitors blocked these inductions). Conversely, an OT antagonist inhibited 
the improved spatial memory, LTP, and CREB Ser133 phosphorylation. 
 
4.4 The CRTC family of CREB co-activators 
In 2003 Conkright and co-workers screened the human genome for potent CRE activators, 
and found the cyclic AMP regulated transcriptional co-activators (CRTC) 1 and CRTC2. A third 
co-activator CRTC3 was identified by BLASTP search of the GENBANK NR database. The 
group named these co-activators originally “transducer of regulated CREB activity (TORC), 
but growing confusion with the mammalian target of rapamycin complex (mTORC) 
convinced the authors to rename the co-activators to  CREB regulated transcriptional co-
activator (CRTC) [also referred to as mucoepidermoid carcinoma translocated protein 
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(MECT)]. CRTC1 is predominantly expressed in the brain, while CRTC2 and CRTC3 are 
ubiquitously expressed (Conkright et al. 2003). CRTCs potentiate CREB activity via a 
phospho-Ser133- independent mechanism by binding CREB via its bZIP domain, thereby 
enhancing the association of CREB with the TAFII130 component of the TFIID and the CREB 
binding protein (CBP) as well as the histone acetyltransferase paralogue p300 (Ravnskjaer et 
al. 2007). This association was shown to be enhanced by lithium, thereby in part explaining 
the mood modulatory activity of lithium by changing CREB dependent gene transcription 
(Heinrich et al. 2013). All three CRTCs have a similar modular structure: an N-terminal CREB 
binding domain (CBD), a central regulatory domain (REG), a splicing domain (SD), and a C-
terminal TAD (Luo et al. 2012).  
A second function of CRTCs is the regulation of alternative splicing. Studies revealed the 
binding of CRTC to the spliceosome factor non-POU domain –containing octamer-binding 
(NONO, also known as p54NRB), to regulate alternative splicing of TATA box-less genes. It 
may be even a mutual process, insofar that CRTCs have no effect on transcription from 
TATA-less promoters, but are competent to promote alternative splicing of these genes. 
Alternative splicing induced by CRTCs does not occur in promoters with a TATA-box, like the 
CRF gene (King and Nicholson 2007). 
13 years ago, it has been discovered that the PKA-mediated phosphorylation of CREB on 
chromatin templates was relatively inefficient, compared to the phosphorylation over naked 
templates, i.e. DNA without any proteins bound to it. This effect was reversed by acetylation 
of nucleosomes, which increases the accessibility to chromatin (Michael et al. 2000). A very 
recent study solved the problem by revealing the recruitment of arginine methyltransferase 
5 (PRMT5) by CRTC2. PRMT5 is a type II methyltransferase that symmetrically mono- or di-
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methylates arginine residues in histone 3. CRTC2 is activated by cAMP, translocates to the 
nucleus, recruits PRMT5 to relevant target gene promoters, which increases nucleosome 
clearance over CREB binding sites (Tsai et al. 2013) by arginine2-di-methylation of the H3. 
This opens the chromatin structure and allows the phosphorylation of CREB by PKA.  
 
Figure 7  Model of gene activation by concerted action of CRTC2 and PRMT5 to allow CREB 
phosphorylation by PKA. Under basal conditions CREB over CREB-binding-sites is not accessible for PKA. An 
extracellular signal induces cAMP production, which activates CRTC2, which in turn recruits PRMT5 to the 
target promoter region. PRMT5 induces nucleosomal clearance over the target region, by di-methylation of 
arginine2 on Histone3, which allows for CREB phosphorylation and subsequent gene expression. taken and 
adapted from (Tsai et al. 2013) 
 
The group of Greti Aguilera could prove the involvement of CRTCs in the transcriptional 
regulation of the CRF gene. CRTC1, 2, and 3 are translocated to the nucleus upon stimulation 
with the adenylate cyclase stimulator FSK in 4B cells and primary hypothalamic neurons, 
where they bind to CREB to activate transcription at the CRF promoter (Liu et al. 2010). 
Further studies on the physiological relevance of this mechanism revealed CRTC2 
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immunoreactivity in magno- as well as parvocellular regions of the hypothalamic PVN. This 
hypothalamic CRTC2 was found to be mostly cytosolic under basal conditions, but 
translocates to the nucleus under stressful conditions (restraint stress). Translocation only 
occurred in parvocellular CRF neurons (Liu et al. 2011). Distribution studies revealed specific 
expression of CRTC subforms in brain nuclei, with CRTC1 being the most abundantly 
expressed subform in the forebrain, while CRTC2 was found to be located in discrete nuclei 
as the PVN, SON and suprachiasmatic nucleus. CRTC3 expression was strong in the 
ependyma and pia mater, whereas being low in the PVN (Watts et al. 2011). Subsequent 
studies revealed SIK2 as the upstream inhibitor under basal conditions, whereas induction of 
SIK1 limits transcriptional activation of CRF expression (Liu et al. 2012). 
  
4.5 Salt-inducible kinase (SIK) 
Under basal conditions, CRTCs are sequestered in the cytosol by phosphorylation-dependent 
binding to the scaffolding protein 14-3-3. This phosphorylation is mainly maintained by the 
salt inducible kinase (SIK). This kinase was first identified as an enzyme induced in the 
adrenal glands of rats fed with a high-salt diet (Wang et al. 1999). The three subforms (SIK 1-
3) belong to the family of AMP-activated protein kinases (AMPKs), which are known to be 
involved in energy homeostasis (Winder and Hardie 1999). SIK1 expression in the 
hippocampus is involved in the development of cortical neurons by regulating CRTC1 
(Feldman et al. 2000; Li et al. 2009). Sasaki et al (2011) found high levels of SIK2 in neurons 
and that a decrease in SIK2 is accompanied by the dephosphorylation of CRTC1. 
Interestingly, the decrease of SIK2 was shown to be induced by CaMKI / IV phosphorylating 
Thr484 in the SIK2 protein, which leads to proteasomal degradation. The CaMKIV activation 
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seems to be dependent on NMDAR subtype NR2A-mediated Ca2+-influx (Sasaki et al. 2011). 
In this way, CaMKIV can activate CREB regulated gene transcription via two separate 
mechanisms: First, via NR2A mediated Ca2+-influx, CaMKIV phosphorylates SIK2, thereby 
leading to its degradation. This inhibits CRTC1 phosphorylation and maintains its nuclear 
activity. Second, CaMKIV phosphorylates CREB at Ser133 directly to activate its 
transcriptional activity. In addition, CaMKIV can also phosphorylate CBP and thereby 
stimulate CREB-dependent transcription (Hardingham et al. 1999; Impey et al. 2002). A Ca2+-
independent inhibitory mechanism is represented by SIK2 phosphorylation at Ser587 by 
cAMP-induced PKA activity. This phosphorylation leads to SIK2 inhibition, but in contrast to 
Thr484 phosphorylation, this is not followed by proteasomal degradation. 
 
4.6 Calcineurin 
Calcineurin (CaN) is a Ca2+-activated protein phosphatase, also known as protein 
phosphatase 3 (PP3). Calcineurin consists of two subunits: a catalytic subunit A, and a 
regulatory subunit B. It was shown to be involved in the dephosphorylation (activation) of 
the CRTCs. This dephosphorylation is Ca2+-dependent, and the expression of TrpV6 was 
shown to induce CaN activity. However, other Ca2+ channels might also play a role in 
activating CaN through Ca2+-influx from the extracellular space. This increase in intracellular 
Ca2+ leads to binding of Ca2+ to calmodulin, and this complex then activates CaN via direct 
interaction with the regulatory subunit (Yamashita et al. 2000). Upon Ca2+-induced activation 
of calcineurin, CRTCs are dephosphorylated and are free to translocate to the nucleus, 
where they bind CREB at its bZIP domain. CRTC itself, like all other transcriptional co-
activators, has no DNA binding activity.  
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4.7 Pin1 and its interactions with ERK1/2 and CRTC2 
Pin1 is a peptidyl-prolyl cis/trans isomerase (also known as NIMA interacting protein), that is 
bound to activated MEK2, which acts as a scaffolding protein. Upon activation by MEK2, Pin1 
has different effects. It has a role in prolonging MAPK signaling by inhibiting the negative 
feedback phosphorylation of Ras (Dougherty et al. 2005), thereby sustaining MAPK cascade 
activity, but has also been shown to inhibit ERK1/2 phosphorylation via a Rho GTPase-
activating protein in the context of cell migration (Pan et al. 2010). This finding is of special 
interest for the work presented in this thesis, because it provides one possible explanation 
for the lack of ERK activation in spite of activated MEK1/2 in the PVN upon OT treatment. 
Pin1 not only inhibits ERK phosphorylation, it also promotes the translocation of CRTC2 out 
of the nucleus and into the cytosol, thereby inhibiting the interaction with CREB (Nakatsu et 
al. 2010). This leads to transcriptional down-regulation, comparable to the inhibition of CRF 
gene transcription described in the results section of this thesis. 
 
5. Aim of the present thesis 
Anxiety-related disorders, caused by chronic and/or psychosocial stress, have become a 
major burden in our modern society, and its impact on our health system is constantly 
increasing (Wittchen et al. 2011). For effective treatment, detailed understanding of the 
molecular machinery that regulates the perception and processing of stressful cues and 
anxiety is urgently needed. 
The neuropeptide OT has received substantial attention during recent years, due to its 
anxiolytic properties revealed in the PVN and amygdala and to its apparent stress-reducing 
activity. As outlined above, OT exerts many other behavioral and physiological effects, so 
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before OT can be of routine pharmacy-therapeutic use for the treatment of anxiety 
disorders, detailed research must unravel how OT brings about its anxiolytic and stress-
protective effects. This not only concerns the cell types and brain regions involved, but also 
the molecular mechanisms at the intracellular level that are at the basis of these effects. 
Especially the latter has not received much attention in the scientific community, because of 
the complexity of intracellular signaling and subsequent control of gene expression and 
neuronal activity. 
The work presented in this thesis aimed to unravel some of the intracellular signaling 
pathways that mediate the anxiolytic and stress-inhibiting effects of OT in the PVN. In the 
first part of my experiments, I aimed to reveal MAPK signaling pathways that are activated 
following OTR activation in male as well as in female rats at different phases of reproduction 
(virgin, pregnant, lactating). The role of some of these signaling pathways in the regulation 
of anxiety will be shown. In the second part, I will describe my efforts to identify a specific 
intracellular signaling pathway, which is activated by OT and reduces the expression of CRF 
during stress.  
The data presented in this thesis reflect the complexity and specificity of intracellular 
signaling pathways that are coupled to the OTR. This might serve as a basis for future 
identification of intraneuronal factors that specifically mediate the anxiolytic and anti-stress 
effects of OT. These factors would make promising candidates for the development of 
specific medication to treat anxiety disorders and to reduce the negative consequences of 
stress. 
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Materials & Methods 
 
1. Animals 
Adult female or male Wistar rats (Charles River, Germany, 220–300 g body weight at the 
beginning of the experiment) were housed under standard laboratory conditions in groups 
of 3 to 4 (12 h light : dark cycle, 22 – 24 °C, lights on at 06.00 h, food and water ad libitum). 
All experiments were performed between 08:00 – 11:00, approved by the government of 
the Oberpfalz, Germany, and performed in accordance with the Guide for the Care and Use 
of Laboratory Animals by the National Institutes of Health, Bethesda, MD, USA. 
For pregnancy related experiments or primary neuron isolation, mating with a sexually-
experienced male (300 – 350 g) was performed after at least one week of habituation.  
Confirmation of pregnancy was accomplished by observing the presence of sperm in vaginal 
smears and designated as pregnancy day 1. 
 
1.1 Surgical procedures 
All surgical stereotaxic procedures were performed under isoflurane anesthesia and semi-
sterile conditions on pregnancy day (PD) 14, lactation day (LD) 2 and in age-matched virgin 
females and males.  Following surgery, rats received an s.c. injection of antibiotic (0.03 ml 
enrofloxacin; 100mg/1ml Baytril, Bayer). Animals were allowed to recover before 
undergoing behavioral or protein phosphorylation assessment six days after surgery (i.e. PD 
20 or LD 8).  Rats were single-housed after surgery and handled daily to habituate them to 
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the respective central infusion procedure and to avoid non-specific stress responses during 
the experiment. 
For analysis of the hypothalamic MAPK pathway in virgin, pregnant and lactating female rats 
under the influence of icv vehicle, OT (Sigma), or MEK1/2 inhibitor (U0126, Sigma) infusion, 
an indwelling icv guide cannula (stainless steel, 21 G, 12 mm long) was stereotaxically 
implanted 2 mm above the right lateral ventricle (AP: −1.0 mm bregma, ML: +1.6 mm lateral, 
DV: +1.8 mm below the surface of the skull; (Paxinos and Watson 1998)) as previously 
described (Blume et al. 2008; Slattery and Neumann 2010).   
To determine the effect of OT on hypothalamic CRF expression, MAPK activation, anxiety-
related behavior, and CRTC translocation, vehicle, OT (Sigma) or (Thr4 Gly7)-OT (TGOT) 
(Bachem) were infused through an indwelling icv guide cannula (stainless steel, 23 G, 12 mm 
long) that was stereotaxically implanted 2mm above the third ventricle (AP: +0.9 mm 
bregma, ML: -1.2mm lateral, DV: +5 mm below the surface of the skull, Angle: 10°; (Paxinos 
1998; Baird et al. 2008; Roy et al. 2008). 
For analysis of local effects of OT within the PVN on anxiety-related behavior, indwelling 
bilateral guide cannulas (stainless steel, 23 G, 12 mm long) were implanted 2 mm above 
both the left and right PVN (AP: -1.4 mm bregma, ML: -1.8 and +2.1 mm lateral; DV: +6 mm 
below the surface of the skull; angle 10°; (Paxinos and Watson 1998; Blume et al. 2008), and 
anchored to two stainless-steel screws using dental acrylic.  The guide cannulas were kept 
viable with dummy cannulas, which were removed daily and cleaned during the handling 
procedure.   
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1.2 Light-dark box 
To assess the effects of OT, TGOT, and MEK inhibitor infusions bilaterally in the PVN / 3rd 
ventricle of males or virgin / lactating female rats on anxiety-related behavior, the animals 
were tested in the LDB seven days after the implantation of the guide cannulas (i.e. LD 8 or 
equivalent in age-matched virgins) and 10 min after the last drug infusion. The LDB test was 
performed as previously described (Waldherr and Neumann 2007; Slattery and Neumann 
2010).  Briefly, the LDB setup consisted of two compartments; one lit compartment (40 x 50 
cm, 350 lux; light box) and one dark compartment (40 x 30 cm, 70 lux).  The floors in each 
compartment were divided into squares (10 x 10 cm) and the compartments were 
connected via a small opening (7.5 x 7.5 cm).  Rats were placed in the dark compartment, as 
described in (Jurek et al. 2012)). In later studies of CRF gene expression, rats were placed in 
the light compartment first, and latency to first light compartment re-entry, as well as line-
crosses, time spent in each compartment, and rearings were assessed during the 5-min test 
on-line via a camera located above the box by an observer blind to treatment.  The time 
spent in the light box by the vehicle/vehicle group was set to 100 % for each experiment. 
 
1.3 Restraint Stress 
To analyze the influence of icv OT or TGOT on basal and stress-induced CRF expression and 
CRTC translocation, four groups of rats were used in separate experiments: (1) a vehicle 
(Ringer) / no stress group, (2) an OT or TGOT / no stress group, (3) a vehicle / stress group, 
and (4) an OT or TGOT / stress group. OT and TGOT are equally effective at the 
concentration applied (1 nmol in 2 µl; compare (Blume et al. 2008; Jurek et al. 2012) with 
(Lukas et al. 2011; Viviani et al. 2011) and have a similar affinity for the OTR (Manning et al. 
 
55 
 
2008)). TGOT was used in some of the experiments to exclude the contribution of the AVP 
receptors to the observed effects. The drugs or their vehicle were infused 10 min prior to the 
restraint stress procedure, and the animals were returned to their home cage during this 
period. Then, the animals were restrained in a Plexiglas column (12 cm diameter) with 
ventilation holes, and were kept there for 10, 15, or 30 minutes. The non-stressed controls 
were time-matched to accommodate for the time of the stressor. Immediately after 
restraint, rats were decapitated, trunk blood was collected and the brains were dissected 
and quickly frozen on dry-ice and stored at -80 °C until cryo-sectioning for CRF expression. 
The brains were cut at a thickness of 250 µm, and the PVN isolated with a tissue puncher 
(Fine Science tools 1.8 mm diameter; (Jurek et al. 2012)). RNA was extracted by addition of 1 
ml of TriFast Gold (PeqLab) to the isolated tissue. Tissue dispersion was achieved by 
extensive vortexing. The lysate was then either frozen at -80°C (for RNA isolation), or 
immediately processed (for protein isolation). For CRTC translocation analysis, non-frozen, 
freshly isolated hypothalami were dissected, the PVN punched out, and transferred to ice-
cold lysis buffer (see below). In addition, cortical tissue served as a control for brain region 
specific effects of stress and OT. 
 
1.4 Verification of cannula placements 
After the experimental procedure, the animals were sacrificed.  For verification of the 
placement of icv cannula, following dissection of the hypothalamus, the rest of the brain was 
snap-frozen in isopentane cooled to -32°C by dry-ice.  Localization of the cannula tract was 
then performed using 40-µm cryosections stained with Nissl and with aid of a rat brain atlas 
(Paxinos and Watson 1998). For PVN cannula verification, blue dye was infused into the PVN 
as described above, then the brain was snap-frozen in isopentane and histological 
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assessment performed as described for the icv cannulas above. Additional verification of 
cannula placement for the 3rd ventricle is the fact that TGOT and AVP infusions into 
neighboring nuclei (i.e. the ventromedial hypothalamus, PVN) at concentrations we used for 
icv infusions (1nmol/2 µl) would lead to immediate severe overdose-effects. 
 
2. Cell culture and stimulation 
2.1 Primary hypothalamic neurons 
Fetal Wistar rats, embryonic d 18, were used to obtain primary hypothalamic neurons. Fetal 
rats were rapidly removed from 18-d pregnant rats after CO2 sedation and decapitation. 
Fetuses were decapitated and hypothalamic tissue dissected and collected in ice-cold buffer 
(pH 7.4, containing 137mM NaCl, 5mM KCl, 0.7 mM Na2HPO4, 25 mM HEPES buffer, and 100 
µg/ml gentamycin). Tissues were then digested for 1.5 h with collagenase type 2 (1 mg/ml; 
Worthington, Lakewood, NJ) dissolved in the buffer mentioned above, supplemented with 1 
mg/ml glucose, 4 mg/ml BSA, and 0.2 mg/ml desoxyribonuclease. The cell suspension was 
filtered through a 40-µm cell strainer (BD Falcon, Heidelberg, GER) centrifuged at 200 g for 
10 min. Cells were consecutively washed twice in dispersion buffer and once in plating 
medium (DMEM/F12, 100 µg/ml gentamycin, and 10% heat-inactivated fetal bovine serum). 
Cells were plated at a density of 1 x 106 cells/well in six-well plates coated with poly-L-lysine. 
After 24 h in the presence of serum, cultures were maintained for eight additional days in 
neurobasal medium containing B27 supplement (Life Technologies, Inc., Invitrogen). 
Cytosine arabinoside (Sigma) was added to a final concentration of 5 µM from day 4 onwards 
to prevent glial cell proliferation. On day 10, growth medium was replaced by supplement-
free neurobasal medium containing 0.1% BSA (protocol adapted from (Liu et al. 2008)). After 
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1h of pre-incubation in this medium, cells were incubated with or without forskolin (FSK, 
1µM, Sigma) and/or the OTR agonist TGOT (10 nM Bachem) for the periods of time indicated 
in the results section. Following this, the cells were harvested and RNA was isolated as 
described below. 
 
2.2 H32 cells 
 The hypothalamic cell line H32 (Mugele et al. 1993) was cultured in Dulbecco's modified 
Eagle's medium (DMEM; Life Technologies, Inc., Gaithersburg, MD, USA) containing 10% 
fetal bovine serum, 10% horse serum and 1% penicillin/streptomycin (Life Technologies, Inc.) 
at 37 °C and 5% CO2. Prior to the experiments, the cells were transferred to 100 mm plates 
at a density of 3×106 cells per plate. 24 h later, the medium was changed to serum-free 
medium containing 0.1% BSA for 2h. To determine the signaling pathways mediating the 
effects of OT, cells were incubated in the presence or absence of FSK (1 µM) and/or TGOT 
(10 nM). After incubation for the time periods indicated in the results section and figure 
legends, cytosolic and nuclear proteins were extracted for Western blot analysis for CRTC2/3 
and pCREB levels as described below. 
 
2.3 Be(2)-M17 cells 
 The human neuroblastoma cell line Be(2)-M17 (European Collection of Cell Cultures, 
#95011816) was cultured in DMEM/F12 (1:1) (Invitrogen/GIBCO) containing L-glutamine, 
2,435 g/L sodium bicarbonate, 15 % heat-inactivated foetal bovine serum (GIBCO), 1 % non-
essential amino acids (GIBCO), and 0.1 mg/ml Gentamycin (GIBCO 15750-060) at 37 °C and 5 
% CO2. Three days before the experiment the cells were allowed to differentiate to neurons 
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by adding retinoic acid (Sigma) to a final concentration of 5 µM. On the day of experiment, 
the cells were incubated in serum-free DMEM/F12 (+ 0.1 % BSA) for 2 h to reduce basal 
activation of gene transcription initiated by any growth factors and steroids that might be 
present in the serum. The TGOT (10 nM) and forskolin (50 µM) stimulation protocols of the 
Be(2)-M17 cells were similar to those described for H32 cells, as were those for protein or 
RNA isolation. 
 
3. Western blot analysis of protein phosphorylation and nuclear translocation 
Cytosolic and nuclear proteins were extracted using a protein extraction kit (Active Motif, 
Rixensart, Belgium). Briefly, single hypothalamic tissue blocks were homogenized in 300 µl 
hypotonic buffer (supplemented with 0.1 mM DTT, 0.1 mM detergent, phosphatase and 
protease inhibitors as included in the kit), and incubated on ice for 15 min. Following 
centrifugation (10 min, 850 g, 4 °C), the supernatant containing cytosolic proteins was 
collected. To ensure complete lysis, the pellet was resuspended in 200 µl of hypotonic buffer 
(supplemented only with phosphatase and protease inhibitors) and incubated on ice for 15 
min. Then 50 µl / ml of detergent was added, the mixture vigorously vortexed and 
centrifuged (3 min, 14,000 g, 4 °C). The supernatant was collected and pooled with the 
supernatant collected earlier to an end volume of 500 µl. The pellet was washed once with 
ice-cold phosphate-buffered saline (PBS), to wash away any remaining cytosolic proteins, 
and resuspended in 100 µl complete lysis buffer, supplemented with DTT, and phosphatase 
and protease inhibitors, as indicated by the manufacturer. The samples were incubated on 
ice for 30 min, then vortexed, centrifuged (10 min, 14,000 g, 4 °C), and supernatants 
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containing nuclear proteins collected. The protein concentrations were determined using 
the Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, USA).  
It should be noted that the vast differences in the protein content of hypothalamic tissue 
blocks, tissue punches, Be(2)-M17 cells and H32 cells brings about the need to apply 
different protein extraction kits. Nuclear extracts from Be(2)-M17 cells and PVN tissue 
punches were prepared using ice-cold NE-PER Nuclear and Cytosolic Extraction Reagent 
(Pierce, Rockford, IL), with added 100 x HALT Protease and Phosphatase Inhibitor (Thermo 
Scientific), according to the manufacturer’s protocol. Western blot analysis was performed 
for CRTC2, CRTC3, pCREB, CREB , Lamin A, ß-tubulin, Ras, histone deacetylase 1, as 
previously described (Liu et al. 2008) with the following modifications. For CRTC3, 15 µg of 
cytosolic or nuclear extract were loaded with a 4x Laemmli Loading Dye (2.0 ml 1M Tris-HCl 
pH 6.8; 0.8 g SDS; 4.0 ml 100% glycerol; 0.4 ml 14.7 M β-mercaptoethanol; 1.0 ml 0.5 M 
EDTA; 8 mg bromophenol blue) and separated in a 6% Tris-glycine gel (Invitrogen). To detect 
CRTC2 from Be(2)-M17 lysates 30 µg of protein were loaded onto the gel. Gels were run until 
the 50 kDa marker (prestained protein ladder, Fermentas, Inc., Glen Burnie, MD, USA) ran 
off the gel, to separate phospho- from dephospho-CRTCs. All other proteins were separated 
on a 10 % Tris-glycine gel. Following electrophoresis, proteins were transferred to a 
polyvinyl-difluoride membrane (GE Amersham) and blocked in Tris-buffered saline with 0.1% 
tween (TBS-T) + 5% milk powder or BSA for 1 h at room temperature. After the transfer, the 
remaining gels were stained with Coomassie-Blue dye to control for even loading and 
transfer of proteins. 
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Target Company Dilution Diluents 
Anti CRTC2 Calbiochem/EDM 1:12.000 In TBS-T 
Anti-CRTC3 Abcam ab91654 1:2000 In TBS-T 
Anti-phospho-CREB Millipore #06-519 1:5000 in 5% BSA 
Anti-CREB Cell signaling #9197 1:1000 In 5% milk powder 
Anti-Lamin A/C Active Motif #39287 1:5000 In TBS-T 
Anti-ß-tubulin Cell signaling #2146 1:1000 In 5% milk powder 
Anti-Ras Abcam ab52939 1:5000 In TBS-T 
Anti-HDAC1 Santa Cruz sc6298 1:1000 In TBS-T 
Anti- GAPDH Abcam ab9485 1:5000 in 2% BSA 
Anti-TATA-box bp Abcam ab63766 1:2000 in 5% BSA 
Anti-p38 Abcam ab32557 1:5000 in TBS-T 
Anti-pMSK Abcam ab81294 1:2000 in 5% BSA 
Anti-pMEK 1/2 Cell Signaling #9154S 1:2000 in 5% BSA 
Anti-MEK 1/2 Cell Signaling #9122S 1:2000 in 5% BSA 
Anti-pERK 1/2 Cell Signaling #9101 1:5000 in 5% BSA 
Anti-ERK 1/2 Cell Signaling #9102 1:5000 in 5% BSA 
Anti-pCaMKIIα Santa Cruz sc-12886-R 1:1000 in TBS-T 
Anti-PEA-15 (Ser104) Cell signaling #2776 1:1000 in 5% BSA 
Anti-PEA-15 (Ser116) Millipore #07-865 1:1000 in 5% BSA 
Anti-PEA-15 Cell signaling #2780 1:1000 in 5% milk powder 
Phospho-c-Jun (Ser63)  Cell signaling #2361S 1:5000 in 5% BSA 
pElk-1 (Ser383) Cell signaling #9181 1:5000 in 5% BSA 
p-mTOR (Ser2481) Millipore #09-343 1:3000 in 5% BSA 
mTOR Cell signaling #2983 1:1000 in 5% milk powder 
Table 1 Antibodies used for western blotting with optimal dilution factor and diluent 
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The blots were blocked with TBS-T containing either 2-5% milk powder or BSA (depending on 
the antibody) for 2 hours at room temperature with gentle agitation. Next, the primary 
antibodies were added, and incubated at the respective dilution (Table 1) overnight at 4°C 
with gentle agitation. After washing and incubating with the appropriate horseradish 
peroxidase labeled secondary antibody (horseradish-peroxidase linked rabbit anti rat (Cell 
signaling) or donkey anti goat (Santa Cruz)), immunoreactive bands were visualized using 
enhanced chemiluminescence plus detection system and film exposure (Liu et al. 2008), or 
with the ChemiDoc XRS+ Imager (Bio-Rad). The intensity of the bands on the film was 
quantified using ImageJ (NIH). Images obtained with the ChemiDoc XRS+ were analyzed with 
the included software. Following imaging, blots were stripped with a mild stripping solution 
(Millipore), or 0.2 N NaOH and assayed for HDAC1 / Lamin A, Ras, GAPDH, TATA box binding 
protein, ß-tubulin, or the respective non-phospho-protein antibody as loading controls. 
 
4. RNA isolation and qPCR 
Punched PVN tissue from the stress experiments were treated with 1 ml TriFast Gold 
(PeqLab), and RNA was isolated according to the protocol provided by the manufacturer 
with some modifications. Briefly, the aqueous supernatant obtained from chloroform 
precipitation with TriFast was added to an RNeasy Mini Kit (Qiagen) column, washed, treated 
with RNase free DNase (according to the manufacturers protocol, Qiagen), washed and 
eluted with nuclease free water. RNA content was determined by means of a NanoDrop 
photospectrometer (Liu and Aguilera 2009). 
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To isolate RNA from the stimulated cells, the medium was aspirated off, and 1 ml of TriFast 
Gold Reagent (PeqLab) was added to the 6-well plates (primary cells) or petri-dishes (Be 
cells), respectively. The remaining cells were scraped off from the petri-dishes by means of a 
sterile cell scraper and collected in RNase free 1.5 ml tubes. From here on, the protocol used 
for RNA isolation was similar to that described for brain punches. 
300 ng of total RNA per sample were used for reverse transcription into cDNA using Super 
Script III First strand Synthesis System for RT-PCR (Invitrogen). Relative quantification of CRF 
hnRNA levels was performed using SYBR Green (QuantiFast Qiagen), using ribosomal protein 
L13A (Rpl13A) and cyclophilin A (CycA) as housekeeping genes (Bonefeld et al. 2008). 
Specificity of the qPCR was assured by omitting reverse transcription and by using ddH2O as 
template. As the results obtained using Rpl13A and CycA yielded similar results, only those 
for Rpl13A are shown. The PCR protocol consisted of an initial denaturation step of 5 min at 
95 °C, followed by 50 cycles of denaturation at 95 °C for 10 s, and annealing/extension at 60 
°C for 45 s. At the end of the protocol a melting curve was generated to confirm the 
specificity of the primers. All samples were run in triplicate. 
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Target name Sequence species Amplicon size 
Rpl13A forward 5’ACAAGAAAAAGCGGATGGTG3’ rat 167 bp 
Rpl13A reverse 5’TTCCGGTAATGGATCTTTGC3’ rat 
CycA forward 5’ AGCACTGGGGAGAAAGGATT3’ rat 248 bp 
CycA reverse 5’AGCCACTCAGTCTTGGCAGT3’ rat 
CRF hnRNA forw 5’ TCAATCCAATCTGCCACTCA3’ rat 154 bp 
CRF hnRNA rev 5’TAAGCTATTCGCCCGCTCTA3’ rat 
CRF hnRNA forw 5’AAGACAACCTCCAGAGAAAG3’ human 324 bp 
CRF hnRNA rev 5’CATCCCAGCTACTATTGTAATC3’ human 
Rpl13A forward 5’TGGCTAAACAGGTACTGCTGG3‘ human 284 bp 
Rpl13A reverse 5’CCGCTTTTTCTTGTCGTAGGG3‘ human 
OTR forward 5’AAGAGCAACTCGTCCTCCTTT 3‘ human 215 bp 
OTR reverse 5’ACAAACATACGCCATCACCT3‘ human 
AVPR1a forw 5’CGCCTTTCTTCATCATCCAG3‘ human 135 bp 
AVPR1a rev 5’AGTCCTTCCACATACCCGTA3‘ human  
AVPR1b forw 5’GGAGGGTAAGGGTTGGAGTT3‘ human 128 bp 
AVPR1b rev 5’GGAGGGTAAGGGTTGGAGTT3‘ human  
CRF ChIP forw 5’- AGTCATAAGAAGCCCTTCCA-3’ human 92 bp 
CRF ChIP rev 5’- CAACACTGAATCTCACATCCA-3’ human 
Table 2 Primer sequences with corresponding amplicon size and species 
 
5. siRNA transfection 
Be(2)-M17 cells were transfected with 33 nM small interfering RNA (siRNA) and 
Lipofectamine RNAiMAX Reagent (Invitrogen), diluted in OptiMEM to inhibit CRTC2 and 
CRTC3 synthesis. siRNA specific for CRTC2 and the negative control Silencer #5 were 
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purchased pre-designed from Ambion/Life Technologies (Darmstadt, Germany). The human 
oligonucleotide sequences were 5’-CUAUAGUCCUGCCUACUUAtt-3’ (sense) for CRTC2, and 
5’-GCACAUCAAGGUUUCAGCAtt-3’ (sense) for CRTC3. After 12 h, transfection medium was 
removed and replaced by DMEM/F12 (supplemented with 0.1% sterile-filtered BSA) for 2 h. 
The cells were then stimulated with FSK and TGOT for 60 min, and gene and protein 
expression were analyzed as described above.  Verification of knockdown was performed by 
RT-qPCR for CRTC2 and CRTC3 mRNA, and at the protein level by applying a RIPA-Buffer 
(Sigma; added with HALT Protease- and phosphatase inhibitor (100x, Thermo Scientific)) to 
the cells to extract whole cell protein lysates. These were immuno-stained by western 
blotting (described above) with the respective CRTC antibodies. 
 
6. Chromatin immunoprecipitation (ChIP) 
To investigate if CRTC3 binds the CRF promoter in vitro, Be(2)-M17 cells (7 x 106 cells) were 
cultured in 75 cm2 flasks (Sarstedt, Nümbrecht, Germany) in growth medium supplemented 
with 5 µM retinoic acid for 3 days until cell number reached 20 x 106 cells. Cells were then 
stimulated with FSK and TGOT for 10 min, as described above. The chromatin IP protocol 
was carried out as described previously (Lichtinger et al. 2007) with some modifications. 
Briefly, the stimulation medium was removed and replaced by 10 ml of 1% formaldehyde 
solution for 10 min at room temperature. Then, glycine was added to a final concentration of 
125 mM and incubated for 5 min at room temperature to stop fixation. Fixed cells were 
washed with ice cold 1x PBS supplemented with 1mM PMSF (Sigma) and harvested with 5 ml 
of the same solution. The cell suspension was centrifuged for 8 min at 370 g and 4 °C, and 
the pellet was frozen at -80 °C until lysis in cell lysis buffer (10mM HEPES, 85 mM KCl, 1 mM 
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EDTA, 1% NP-40). Next, the nuclei were sonicated 8 times for 10 sec (30 sec sample cooling 
between each sonification step) at output control 2 (Branson Sonifier 250) in nuclear lysis 
buffer (50 mM Tris/HCl, 1% SDS, 0,5% Empigen BB, 10 mM EDTA, 1 mM PMSF, 1x protease 
inhibitor (Roche)) to produce 0.2 to 1 kbp DNA fragments of chromatin. 
Immunoprecipitation was performed with either 4 µg of CRTC3 antibody (Abcam, ab91654), 
rabbit IgG (Qiagen) as negative control, and polymerase II antibody as positive control 
(Qiagen) at 4°C under rotation overnight. DNA-protein-antibody complexes were collected 
using Protein A Sepharose beads, washed, eluted, reverse cross linked, treated with 
Proteinase K and cleaned up with Qiaquick PCR purification columns (Qiagen). 
Immunoprecipitated CRF promoter was quantified using quantitative real-time PCR with 
primers designed to amplify the human CRF promoter region containing the cyclic AMP 
responsive element (CRE) (forward: 5’- AGTCATAAGAAGCCCTTCCA-3’; reverse: 5’- 
CAACACTGAATCTCACATCCA-3’). 
7. Statistical analyses 
Signaling and behavioral data were analyzed using either a one-way or a two-way analysis of 
variance (ANOVA, factors reproductive state x treatment, factors treatment 1 x treatment 2).  
Behavioral data is expressed in comparison to vehicle-treated groups of both virgins and 
lactating dams, as the experiments were performed separately. Any overall statistical 
differences, which were set at P < 0.05, were further analyzed using a Fisher’s or Student 
Newman-Keuls post-hoc test.  Separate parametric t-test between two groups or non-
parametric Mann-Whitney U tests (MWU) were performed.  Data are expressed as group 
mean ± S.E.M.  Statistical analyses were performed using SPSS for Windows (version 16; 
SPSS Inc, Chicago, IL, USA) and Sigma Plot (version 11.0; Systat Software Inc.).
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Results 
Part I: Differential effects of oxytocin on MAPK activity 
 
[partly adapted from: Jurek B, Slattery DA, Maloumby R, Hillerer K, Koszinowski S, et al. 
(2012) Differential Contribution of Hypothalamic MAPK Activity to Anxiety-Like Behavior in 
Virgin and Lactating Rats. PLoS ONE 7(5): e37060. doi:10.1371/journal.pone.0037060] 
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van den Burg: study design, writing the manuscript, data analysis 
all other experiments that were not part of the publication were planned, conducted, and 
analyzed by the author 
 
 
68 
 
Introduction to Part I 
The c-Raf – MEK1/2 – ERK1/2 mitogen-activated protein kinase (MAPK) pathway is one of 
the most important and best-studied intracellular signaling pathways. This pathway conveys 
extracellular signals to intracellular effectors via activation of a variety of cell membrane 
receptors, and hence is responsible for a battery of effects (for detailed description see 
General Introduction). In the brain, ERKs are strongly activated by synaptic stimulation, and 
are essential for the induction and maintenance of synaptic plasticity that is thought to 
underlie memory and learning (Davis and Laroche 2006). Furthermore, ERKs have been 
shown to regulate social behaviors, including social memory and aggression, particularly via 
ERK2 (Satoh et al.). These effects overlap, at least partially, with those reported for the 
neuropeptide OT, and indeed it has been shown that OT activates the MAPK pathway within 
the hypothalamic PVN via transactivation of the EGFR to regulate anxiety in male rats (Blume 
et al. 2008).  Interestingly, the related nonapeptide, AVP, has been shown to activate the 
MAPK pathway in vitro (Chen et al. 2008) and also in vivo (Du et al. 2008; Oligny-Longpre et 
al. 2012). However, it has been repeatedly demonstrated that exogenous central 
administration of AVP has an anxiogenic effect in the amygdala (Landgraf and Neumann 
2004) and that its expression level within the PVN correlates negatively with anxiety-related 
behavior (Murgatroyd et al. 2004; Bunck et al. 2009).  
In females, the brain OT system is particularly active during the peripartum period with 
elevated rates of synthesis of the neuropeptide and its receptor, enhanced local release, and 
receptor binding within limbic and hypothalamic regions (for review see (Brunton and 
Russell 2008; Slattery and Neumann 2008; Hillerer et al. 2011)). Such high brain OT levels are 
important to induce anxiolysis during lactation (Carter et al. 2001; Windle et al. 2004). Also, 
OT enhances spatial memory in the hippocampus of lactating rats, thought to improve the 
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recollection of locations where food and water are present, and thus to reduce the time the 
mother needs to spend finding resources and leaving the pups unattended (Tomizawa et al. 
2003). This effect of OT on spatial memory depends on the activation of ERK, and one of its 
downstream effectors, the transcription factor CREB (Tomizawa et al. 2003). This example, 
together with the anxiolytic effect described above in males, shows the importance of 
ERK1/2 and its kinase MEK1/2 as intracellular mediators of the behavioral effects of OT 
signaling. Further, it shows that the MAPK signaling pathway is recruited during lactation in 
the hippocampus, and that its recruitment depends on OT. Moreover, given lactation-
associated anxiolysis, and the role of both OT and MAPK in anxiety, this pathway may be 
necessary for this effect. However, the roles of MEK1/2 and ERK1/2 in the PVN of females as 
effectors of anxiety-related behavior have not been reported to date. This is nevertheless of 
particular importance considering the mood changes that frequently occur at peripartum in 
humans ((Hillerer et al. 2011) and references therein), and the reported pro-social and 
anxiolytic effects of OT in males and females, in rats as well as in humans (Landgraf and 
Neumann 2004; Kosfeld et al. 2005; Blume et al. 2008; Labuschagne et al. 2010; Meyer-
Lindenberg et al. 2011; Viviani et al. 2011).  
Therefore, the present data is concerned with the central question of whether MAPK 
pathway activity within the PVN of female rats is necessary for an anxiolytic phenotype. To 
address this, we employed two distinct approaches: (1) acute pharmacologically-induced 
(i.e. application of exogenous OT), and (2) long-term physiologically-induced (i.e. lactation) 
anxiolysis and assessed their effects on the MAPK pathway within the PVN (adapted from 
(Jurek et al. 2012). 
 
70 
 
 
Outline of experimental protocols part I 
Experiment 1. Effect of intra-PVN infusion of OT on anxiety-related behavior in virgin and 
lactating rats, and effects of local pre-treatment with the MEK1/2 inhibitor, U0126 
The following experiment was performed in order to (i) unravel the anxiolytic effects of OT, 
infused into the PVN, as a function of the reproductive status of female rats, and (ii) 
determine the role of the MEK1/2 – ERK1/2 signaling cascade in the anxiolytic effect of both 
OT and lactation. Thus, conscious virgin and lactating rats received two subsequent bilateral 
PVN infusions. They were pre-treated with either vehicle (0.5 µl; 10 % DMSO in Ringer 
solution, pH 7.4, Braun) or the MEK inhibitor U0126 (0.5 nmol/0.5 µl) bilaterally within the 
PVN 5 min prior to infusion of either vehicle, or OT (0.01 nmol/0.5 µl). This experimental 
design gives four different groups: vehicle/vehicle, vehicle/OT, U0126/vehicle or U0126/OT. 
After each infusion, the cannulas were kept in place for 30 s to allow local substance 
diffusion. Anxiety-related behavior was assessed in the light-dark box (LDB) 10 min later. The 
doses were chosen based on previous studies (Blume et al. 2008).   
 
Experiment 2. Determination of basal and OT-induced MEK1/2 and ERK1/2 activation within 
the hypothalamus of virgin, pregnant, and lactating rats 
To assess the impact of reproductive status under basal and acute icv OT conditions on 
hypothalamic MEK1/2 and ERK1/2 activation, conscious well-handled virgin, pregnant 
(PD20), and lactating (LD8) rats received either an acute vehicle (5 µl; Ringer solution, pH 
7.4, Braun) or OT (1 nmol) infusion. Ten minutes later, rats were decapitated and the 
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hypothalami dissected, immediately frozen, and stored at -20°C until further processing. The 
hypothalamus was dissected rostrally at the level of the optic chiasm, and caudally through 
the median eminence. Laterally, the lateral ventricle was used as a landmark to remove the 
most lateral parts of the hypothalamus. Dorsally, the third ventricle represented the top 
most level of the PVN-enriched region. The suprachiasmatic and remaining part of the 
supraoptic nuclei were also removed. This results in a hypothalamic tissue block containing 
mostly the PVN with some bed nucleus of the stria terminalis, medial preoptic area, and the 
anterior hypothalamic nuclei (Paxinos and Watson 1998). 
 
Figure 8  Schematic representation of PVN-enriched hypothalamic tissue that was extracted for 
western blot analyses. Scale bar: 1 mm; adapted from (Jurek et al. 2012) 
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Experiment 3. Effects of blockade of MEK1/2 activity on basal and OT-induced ERK1/2 
activation within the hypothalamus 
To assess if icv pre-treatment with the MEK1/2 kinase inhibitor, U0126, reduced basal or OT-
induced ERK1/2 activation in virgin or lactating (LD8) rats, the following groups were 
compared: vehicle/vehicle, U0126 (1nmol)/vehicle, vehicle/OT (1 nmol) or U0126/OT.  The 
icv infusions were 10 min apart, and 10 min after the second infusion, the hypothalami were 
isolated as described in Experiment 2. 
 
Experiment 4. Assessment of activated signaling cascades and transcription factors within 
the PVN of male or virgin female rats, induced by an intra-PVN, lateral ventricle, or 3rd 
ventricle infusion of OT or TGOT, and consequences for anxiety-like behavior 
4.1 Effects of several application protocols on the intracellular signaling were assessed and 
compared to gain insight into intracellular processes coupled to the OTR. (i) Activation of 
cytosolic MEK1/2 and ERK1/2 in males 10 min after either icv (1nmol / 5µl) or intra-PVN 
(0.01 nmol / 0.5 µl) infusion of OT or vehicle was measured and compared by western 
blotting. (ii) To prevent tissue damage in the PVN caused by the application cannula or 
pressure of the liquid infused, which might interfere with MAPK activation, we applied TGOT 
(1nmol / 2µl, dissolved in Ringer solution, pH 7.4, Bachem) or vehicle (Ringer solution, 
Braun) to the adjacent 3rd ventricle, allowed substance diffusion for 30 s, returned the 
animals to their home-cage and decapitated them after 10 min. A precise isolation of the 
hypothalamic PVN, using a tissue puncher (1.8 mm diameter, Fine science tools) with fresh, 
non-frozen tissue was applied, which reduces the protein concentration obtained, but 
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excludes possible contamination from nearby hypothalamic nuclei. TGOT was used to 
exclude non-specific VP-receptor-activation effects on MEK1/2 and CaMKII, as well as to 
assess ERK1/2 and PEA-15 activation. In addition, PEA-15 activation, mTOR and Elk-1 
phosphorylation by 250 nM OT was assessed in hypothalamic H32 cells. 
4.2 After the characterization of intracellular signaling pathways that are activated by OT, we 
assessed whether they influence anxiety-like behavior when stimulated by an infusion of 
TGOT into the 3rd ventricle. 10 min after the infusion of TGOT or vehicle, male rats were 
tested in the LDB for anxiety-like behavior as described above. 
 
Experiment 5. Assessment of sex-specific differences in the pathway leading to CREB 
phosphorylation by 3rd ventricle infusion of OT 
To determine whether the intracellular pathway that leads to the phosphorylation of CREB 
are differentially recruited by OT in male and female Wistar rats, we infused OT (1nmol / 2µl) 
or vehicle into the 3rd ventricle of rats of both sexes, isolated the PVN after 10 min as 
described above, and assessed protein phosphorylation in the hypothalamic lysates by 
western blotting. 
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Results Part I 
 
Experiment 1. Effect of intra-PVN infusion of OT on anxiety-related behavior in virgin and 
lactating rats, and effects of local pre-treatment with the MEK1/2 inhibitor, U0126 
In virgin rats, ANOVA did not reveal a significant effect of either bilateral infusion of U0126 
(F(1,29) = 2.21; p = 0.15) or OT (F(1, 29) = 3.59; p = 0.068) directly into the PVN on the relative 
time spent in the light compartment of the LDB.  However, separate analyses revealed a 
significant anxiolytic effect of an OT infusion (MWU; p = 0.009 versus Veh/Veh group;  Figure 
9A) while there were no significant differences between the three other groups. This effect 
was not paralleled by altered locomotor activity as the number of line-crosses in the dark 
compartment did not differ between the treatment groups (data not shown).  
In contrast to the effect observed in virgins, a significant effect of MEK1/2 inhibition on 
anxiety was observed in lactating rats (F(1,32) = 11.3, p = 0.002). Specifically, U0126 treatment 
increased basal anxiety in lactating rats (p < 0.05 versus Veh/Veh,  Figure 9B) without 
altering locomotor activity (data not shown). Interestingly, bilateral intra-PVN infusion of 
synthetic OT did not affect anxiety in lactation (F(1,32) = 3.08; p = 0.089;  Figure 9B) (adapted 
from (Jurek et al. 2012)).   
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 Figure 9 The effects of acute bilateral PVN administration of vehicle (Ringer solution; Veh), or OT (0.01 
nmol/0.5ul) after intra-PVN pre-treatment with either vehicle (DMSO) or the MEK 1/2 inhibitor, U0126 (0.5 
nmol/0.5ul) on time spent in the light compartment of the LDB in (A) virgin rats and (B) lactation day 8 rat 
dams.  Data represent mean ± SEM (n = 7 – 12 per group). Two-way ANOVA was performed followed by 
Fisher’s LSD post-hoc tests where appropriate.  * p < 0.05 compared with vehicle treatment and # p < 0.05 
compared with respective virgin group (adapted from (Jurek et al. 2012)). 
 
 
Experiment 2. Determination of basal MEK 1/2 activation within the PVN in virgin and 
lactating rats 
To determine whether reproductive status altered hypothalamic MEK1/2 activation within 
the PVN, we analyzed phosphorylated MEK1/2 (pMEK1/2) levels relative to total MEK and 
protein content in virgin and lactating (LD8) rats. pMEK1/2 levels appeared to be 24 ± 7% 
higher in the cytosolic fraction of lactating than in virgin rats (p = 0.04), and this applied to 
both, the pMEK/MEK and the pMEK/GAPDH ratio (Figure 10). The MEK/GAPDH ratio was 
similar in both groups, indicating that the increased pMEK1/2 concentration is due to 
increased phosphorylation, rather than to increased MEK synthesis during lactation. There 
were no effects of reproductive state on nuclear MEK phosphorylation or content (data not 
shown) (adapted from (Jurek et al. 2012)). 
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Figure 10 MEK phosphorylation as function of reproductive status in female rats. Representative blot of 
cytosolic pMEK and MEK from PVN protein extracts from virgin and lactating rats. Cytosolic pMEK levels were 
higher in the PVN of lactating rats when compared with total MEK and total protein (as measured by GAPDH 
amount), whereas total MEK levels were similar in both groups. Data relative to virgin control value of 1. Mann-
Whitney U-test, * p < 0.05. (adapted from (Jurek et al. 2012)) 
 
Experiment 2.1. Determination of basal ERK1/2 activation within the PVN in virgin, pregnant, 
and lactating rats 
Cytosolic pERK1, but not pERK2, levels relative to both loading controls (GAPDH and β-
tubulin; the latter not shown) tended to decrease in late-pregnant rats, and this effect 
reached significance in lactating rats (to 51.4% relative to virgin; F(2,17) = 6.65; p = 0.009;  
Figure 11A).  
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Figure 11  ERK phosphorylation status in cytosolic (left) and nuclear (right) protein fractions 
from PVNs of virgin, pregnant, and lactating rats. Above; representative cytosolic and nuclear blots. A, ERK 
phosphorylation in the cytosol tended to increase during pregnancy and lactation when corrected for the 
amount of total kinase, although not significantly. B, Cytosolic pERK levels did not change during peripartum, 
when corrected for total protein amount (as measured by GAPDH levels). C, Cytosolic ERK1 concentration 
decreased during lactation, when compared with total protein amount. D, Nuclear pERK/ERK ratio is constant 
over the peripartum period. E, pERK1 levels were elevated in the nuclear fraction of lactating animals, when 
corrected for total amount of protein (as measured by TBP levels). F, Nuclear total ERK1 levels were elevated in 
lactating rats. ANOVA was performed followed by Bonferroni´s post-hoc tests (adapted from (Jurek et al. 
2012)). 
 
In parallel, the nuclear pERK1 content increased in lactating rats as measured relative to the 
TATA box binding protein (TBP) loading control (1.6-fold increase relative to levels in virgins; 
F(2,17) = 5.68; p = 0.016; Figure 11E). This was accompanied by a similar increase of the 
ERK1/TBP ratio (1.5-fold increase; F(2,17) = 4.17; p = 0.04; F). The ratio of pERK1/ERK1 was, in 
contrast, constant in both cellular compartments (Figure 11A, D), indicating that in lactating 
rats, but not in late-pregnant rats, ERK1 is phosphorylated, and subsequently translocated to 
the nucleus (adapted from (Jurek et al. 2012)). 
 
Experiment 2.2. Determination of OT-induced MEK and ERK1/2 activation within the PVN in 
virgin and lactating rats 
Infusion of OT (1 nmol icv) increased pMEK levels, relative to total MEK and protein content, 
by 24 ± 9 % in the cytosolic fraction of PVN tissue of virgin rats (p = 0.049; Figure 12). 
Surprisingly, MEK activation was not accompanied by increased ERK1/2 phosphorylation in 
virgins (Figure 12A). In lactating rats, where brain OT activity is already high, pMEK levels 
were decreased in response to icv OT (-27 ± 9 %; p = 0.049 versus lactating, vehicle-treated 
rats; Figure 12B). Again, the icv OT infusion did not alter pERK1/2 levels in both fractions. 
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Figure 12 The effect of acute icv administration of OT on MEK and ERK phosphorylation in the cytosolic 
fraction of PVN tissue of virgin and lactating rats. In virgins, OT induced the phosphorylation of MEK, but not 
ERK, while in lactating rats OT induced dephosphorylation of MEK, without affecting pERK levels. Total MEK and 
ERK levels did not change (not shown). Data are relative to Veh groups for each reproductive state. MWU-test, 
* p < 0.05. (adapted from (Jurek et al. 2012)) 
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Experiment 3. Effects of blockade of MEK1/2 activity on basal and OT-induced ERK1/2 
activation within the hypothalamus 
As the OT-induced phosphorylation of MEK1/2 appeared to be uncoupled from the 
phosphorylation of ERK1/2, we inhibited the activity of pMEK1/2 pharmacologically with 
U0126 (1 nmol in DMSO, icv) to determine whether pMEK1/2 exerts ERK1/2 phosphorylation 
activity in the PVN of female rats. Treatment with U0126 lowered basal pERK1/2 
concentrations to a similar extent in both virgin and lactating rats to 52.9% (pERK1) and 
58.4% (pERK2) of control levels (p = 0.019; Veh; DMSO treated rats; Figure 13), indicating 
that pMEK1/2 is indeed a kinase of ERK1/2 in the PVN of female virgin and lactating rats – 
under basal conditions (adapted from (Jurek et al. 2012)). 
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Figure 13 The effect of acute icv administration of U0126 on ERK1/2 phosphorylation in the cytosolic 
fraction of the PVN of lactating rats. U0126 reduced phosphorylation of both ERK1 and ERK2; highly similar 
results were obtained in virgin animals (not shown). Data are expressed relative to respective Veh control 
group. MWU-test, * p < 0.05. (adapted from (Jurek et al. 2012)). 
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Experiment 4. Activated signaling cascades within the PVN of male rats induced by an OT 
infusion into the lateral ventricle, versus a bilateral PVN- infusion 
To assess if the uncoupling of MEK1/2 from ERK1/2 is sex-specific and/or depends on the 
infusion site, we infused OT in either the lateral ventricle or bi-lateral into the PVN of male 
rats and analyzed the phosphorylation status of hypothalamic MEK1/2 and ERK1/2. Infusion 
of OT into the lateral ventricle increased the level of pMEK1/2 1.5 fold when compared to 
vehicle infused rats (p < 0.05, Figure 14A). An intra-PVN infusion increased pMEK1/2 levels in 
the PVN almost 1.6 fold (p <0.05) with no changes in the total amount of MEK, pointing 
toward an increased phosphorylation/activation of already present MEK with no changes in 
protein synthesis. Surprisingly, like in females, OT infusion in the lateral ventricle or the PVN 
did not produce a measureable increase of pERK1/2 levels in the PVN, nor did it influence 
the total amount of ERK1/2. 
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Figure 14  Activated MAPK cascades by an OT infusion into the lateral ventricle versus a bi-
lateral intra-PVN infusion in male rats. A, OT phosphorylates MEK1/2 when infused into the lateral ventricle 
(1nmol/5µl) or bi-lateral intra-PVN (0.01 nmol/0.5 µl), whereas (B) activation of ERK1/2 is absent in icv as well 
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as in intra-PVN infused hypothalami. Data are expressed relative to respective Veh control group. Tub, ß-
tubulin. t-test, * p < 0.05. 
 
Experiment 4.1. Activated signaling cascades within the PVN of male rats induced by a TGOT 
infusion into the 3rd ventricle. 
As OT infusion in male rats leads to MEK activation, but not ERK1/2 phosphorylation, we 
investigated if binding of OT to the VP receptor plays a role in the uncoupling of MEK from 
ERK. To address this issue, rats were infused with the highly specific OTR agonist TGOT 
(1nmol/2µl) into the 3rd ventricle to determine protein phosphorylation. Comparable to 
virgin females, OTR activation by TGOT induced MEK and also CaMKII phosphorylation 
(Figure 15A,B) with an almost 2 fold increase compared to vehicle infused rats (p = 0.001 for 
pMEK, p = 0.047 for pCaMKII n = 7-8). Again, the ratio of pERK / ERK in the cytosol or nucleus 
was not affected by OTR activation (data not shown). 
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Figure 15 TGOT (1 nmol / 2 µl) infused into the 3rd ventricle of non-stressed male rats (TGOT) increases 
pMEK (A) and pCaMKII (B) in the cytosolic fraction of PVN homogenates. Representative western blot show the 
TGOT-induced increase of pMEK and pCaMKII relative to Veh controls. Phosphorylated protein was normalized 
to GAPDH. n = 7-8 in all groups;*p < 0.05 versus Veh 
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To further study the lack of involvement of pERK1/2 in OTR mediated signaling, we 
monitored the phosphorylation status of the scaffolding protein PEA-15 upon OT stimulation 
in vivo and H32 cells. OTR activation induces CaMKII (Figure 15B) and PKC phosphorylation 
(Gimpl and Fahrenholz 2001), two kinases that phosphorylate PEA-15, a necessary pre-
requisite for the release of pERK1/2 from PEA-15 and nuclear translocation of the ERKs. In 
line with the apparent lack of ERK1/2 phosphorylation (despite the activated MEK1/2) we 
found no increased phosphorylation of PEA-15 at Ser116 (CaMKII) in virgin female rats 10 
min after infusion of OT (1 nmol / 5 µl) into the lateral ventricle (Figure 16). PEA-15 
phosphorylation is regulated hierarchical with Ser116 phosphorylation preceding Ser104 
phosphorylation. Thus, a lack in Ser116 phosphorylation indicates no subsequent Ser104 
phosphorylation. 
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Figure 16  OT (1 nmol / 5 µl) infused into the lateral ventricle of non-stressed female virgin rats 
(OT) did not affect pPEA-15 (Ser116) in the cytosolic fraction of PVN homogenates (p = 0.152). Original western 
blot showing Veh vs. OT-induced pPEA-15 values (lower band, 15 kDa) normalized to GAPDH (upper band, ~37 
kDa). The membrane was immunostained simultaneously with both antibodies. n = 4-5 
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Further, to exclude effects of OT at later time points, PEA-15 phosphorylation was monitored 
in H32 cells after 10, 20, 30, or 60 min of OT (250 nM) stimulation (Figure 17). In conclusion, 
OT was ineffective in phosphorylating PEA-15 in vivo and in vitro for up to 60 min. 
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Figure 17  Time course of PEA-15 phosphorylation induced by OT (250 nM) at (A) Ser116, and 
(B) Ser104 in H32 cells. OT stimulation has no significant effect on the phosphorylation of PEA-15 at Ser116 or 
Ser104. Data are expressed as mean ± SEM, normalized to total PEA-15, n = 4 in all groups 
 
 
Additional evidence for our model of OT-induced MEK, but not ERK activation and its 
inhibited nuclear translocation is represented by the lack of phosphorylation of the ERK-
activated transcription factor Elk-1 after OT stimulation in H32 cells (data not shown). 
Another important downstream target of the MAP kinase pathway is the central regulator of 
protein synthesis, mTORC. This complex unifies literally every signaling cascade discussed in 
this thesis, to regulate de novo protein synthesis. We assessed whether OT activates this 
complex by phosphorylation, in order to regulate protein synthesis, which might be the 
molecular underpinning of OTs long term anxiolytic effect. Due to the many phosphorylation 
sites of the mTOR complex, we determined the activation status by monitoring the 
autophosphorylation-site. All activating signals lead via different mechanisms to the 
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phosphorylation of this specific Ser2481, and therefore to the activation of the complex. To 
our surprise, we could not detect any influence of OT on mTOR phosphorylation, in vitro 
(250 nM; 30 min stimulation of H32 cells), nor in vivo (Martinetz et al., manuscript in 
preparation), thereby excluding mTOR as downstream target of OTR activation. 
Nevertheless, OT could influence protein synthesis by activating the eukaryotic elongation 
factor 2 (eEF2), and indeed, time dependent activation of this regulating factor by OT in an in 
vitro assay was found in our lab (Martinetz et al., manuscript in preparation).  
 
Experiment 4.2. Assessment of the anxiolytic effect of TGOT infused into the 3rd ventricle 
Previous work has shown that an OTR antagonist infused into the lateral ventricle has no 
effects on anxiety-like behavior (Neumann et al. 2000). As OT binds the vasopressin 1A 
receptor with high affinity, and AVP is anxiogenic, its anxiolytic activity may have been 
masked by simultaneous activation of both receptors. We therefore assessed whether the 
highly specific OTR agonist TGOT reduces anxiety-like behavior when infused into the 3rd 
ventricle. However, TGOT, applied at 1 nmol / 2 µl did not modulate any anxiety or 
locomotor-related behavior parameter measured on the LDB (data not shown), supporting 
the view that OT needs to be secreted in specific brain regions (PVN and amygdala) to bring 
about anxiolysis. 
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Experiment 5. Assessment of sex-specific differences in the pathway leading to CREB 
phosphorylation by 3rd ventricle infusion of OT  
Infusion of OT into the 3rd ventricle of virgin female rats did not activate the CREB-regulating 
MAPK p38 (Figure 18A), whereas in males a slight, yet significant increase of phosphorylated 
p38 could be detected (Figure 18B, p=0.028, n=7). p38 is one of several upstream kinases of 
MSK1/2, and accordingly, MSK1/2 appeared activated in the PVN of males, and, somewhat 
surprisingly, in females (1.5-fold in males, p=0.009, and 3.5-fold in females, p=0.029, n=5-7). 
It is thus possible that MSK1/2 is activated by pp38 in males and by a yet unknown factor in 
females. The downstream effector of MSK1/2 is the transcription factor CREB, which was 
found to be activated by OT in males ((1.5 fold, p=0.011, n=7)) and females (2.3 fold, p=0.02, 
n=4)). 
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Figure 18  Sex specific activation of MAPK pathways leading to CREB phosphorylation. A, 
Infusion of OT into the 3rd ventricle of virgin female rats does not activate the MAPK p38, whereas 
phosphorylation levels of MSK1/2 and its downstream transcription factor CREB increase 3,5 fold or 2,2 fold, 
respectively. B, In contrast to females, p38 could be the OT-induced upstream kinase of MSK, which in turn 
phosphorylates CREB. Data relative to respective control value of 1 (t-test, * p < 0.05, n=4-7) 
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Summary Part I 
The data presented in Part I reveal a tonic activation of MEK1/2 and ERK1 within the PVN 
during lactation, but not during late pregnancy or in virgin animals. OT infused into the PVN 
is anxiolytic and activates MEK1/2 in virgin rats. Blocking the activity of MEK1/2 in virgin rats 
prevented the anxiolytic activity of OT, and caused even a profound anxiogenic phenotype in 
lactating rats (in the absence of exogenous OT). Anxiolysis was exclusively observed when 
OT was applied into the PVN of virgin rats, whereas lateral or 3rd ventricle infusions 
increased hypothalamic pMEK1/2 levels in males and females, but was without effect on 
anxiety-related behavior. Surprisingly, OT infusion in lactating rats reduced MEK1/2 
phosphorylation and was without effect on anxiety-related behavior, suggesting a highly 
dynamic and context-dependent role for MEK1/2 in OT-induced behavior. Moreover, the OT-
activated MEK1/2 in virgin female and male rats displayed no kinase-activity for ERK1/2, 
providing evidence for a yet unknown downstream target of OTR-coupled MEK1/2 in the 
hypothalamus. The lack of ERK1/2 phosphorylation is supported by the observation of 
inactive PEA-15 and the ERK1/2 downstream target Elk-1. Furthermore, activation of the 
canonical p38 - MSK1/2 - CREB pathway in males, or a similar but p38-independent pathway 
in females, could provide one molecular mechanism of OT-induced gene transcription. CREB 
mediated CRF transcription and OT’s role in its regulation will be addressed in Part II.  
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Part II: Stress and oxytocin; molecular mechanisms that regulate CRF gene expression 
 
 
 
(Adapted from: Benjamin Jurek, David A. Slattery, Ying Liu, Inga D. Neumann, Greti Aguilera, 
Erwin H. van den Burg (2013) Oxytocin regulates CRF gene transcription via altered 
translocation of CREB-regulated transcription coactivator 3 (CRTC3), in preparation) 
Author’s contribution: 
Jurek: study design, protein isolation, SDS Page, Western Blot, primary cell isolation and 
culturing, cell culture with cell lines H32 and Be(2)-M17, cell stimulations, knock down by 
siRNA, Chromatin IP, data analysis in all experiments, writing the manuscript  
Slattery: study design, brain isolation in in vivo Experiments, writing the manuscript 
Liu: technical help with primary neuron isolation, cell culture and western blotting at NIH 
Aguilera: study design, technical help with primary neuron isolation at NIH, writing the 
manuscript 
Neumann: study design, writing the manuscript 
van den Burg: study design, writing the manuscript 
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Introduction to Part II 
The neuropeptide CRF, synthesized in the PVN, is the main activator of the HPA axis during 
stress. Following its release into the median eminence, CRF stimulates the release of ACTH 
from the pituitary gland. CRF-producing neurons are under negative feedback from 
glucocorticoids to prevent the detrimental effects of long-term HPA axis activity. CRF cells 
are further regulated by other factors during stress, including the neuropeptide OT 
(Neumann et al. 2000; Windle et al. 2004). Known for its role in reproduction in the 
periphery, central OT promotes prosocial behavior and dampens the neuroendocrine stress 
response (de Kloet et al. 2005; Neumann and Landgraf 2012). Both elevated endogenous 
levels of OT protein and mRNA, as observed during the peripartum period (Neumann et al. 
2000; Hillerer et al. 2011), as well as chronic infusion of synthetic OT (Windle et al. 2004), 
reduce the stress-induced ACTH response in rats. However, former studies have reported  
potentiating effects of peripheral OT on CRF (Antoni et al. 1983) or  stress-induced ACTH 
release (Gibbs et al. 1984; Petersson et al. 1999; Ondrejcakova et al. 2010); thus, the role of 
OT in the control of CRF synthesis and release remains enigmatic. Intriguingly, OT is released 
within the PVN during or immediately after stress (Engelmann et al. 1999), and OTRs are 
located on magnocellular CRF cells within this region (Dabrowska et al. 2013).  Thus, it is 
feasible that OT can influence CRF synthesis and release directly within the PVN, and hence 
HPA axis-activity. 
One of the early hallmarks of CRF cell activity during stress is increased CRF gene 
transcription via a cAMP/PKA-dependent mechanism; presumably to replenish protein 
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stores within the cells (Aguilera and Liu 2011). The downstream binding of pCREB to a cAMP-
responsive element in the promoter is accompanied by binding of one or more of the three 
known CRTCs to CREB. Under basal conditions, CRTC is phosphorylated and resides in the 
cytoplasm, bound to the scaffolding protein 14-3-3. Following its dephosphorylation, CRTC 
translocates to the nucleus where it binds CREB via its bZIP domain and recruits CBP/p300 to 
the CRF promoter for gene transcription to commence (Conkright et al. 2003; Liu et al. 
2011). 
While it remains unknown whether OT influences CRF gene transcription, in the 
hippocampus both OT and stress induce the phosphorylation of CREB (Tomizawa et al. 
2003), which led us to hypothesize that OT regulates CRF expression by controlling the 
translocation and, therefore, nuclear availability of the CREB co-factor CRTC2 or 3. Besides 
CRTC3, the related CRTC2 has been shown to play an important role in the regulation of CRF 
gene transcription (Liu et al. 2011), but to our knowledge, it is not clear to which extent 
CRTC2 and CRTC3 share their modulating potential on CRF gene transcription in vivo. 
Therefore, the aim was to determine whether OT, concomitant to the reduction of stress-
induced ACTH release, may inhibit CRF gene transcription through phosphorylation of one or 
more of the CTRCs. 
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Outline of experiments part II 
Experiment 6. Assessment of the effect of exogenous OT, applied in the 3rd ventricle, on CRF 
gene expression and plasma ACTH 
Male Wistar rats were infused with OT (1nmol / 2µl, 3rd ventricle) or vehicle (Ringer), and 
stressed by restraint 10 min later as described above, and PVN tissue and trunk blood were 
collected for CRF gene expression and ACTH concentration, respectively. Primers targeting 
the rat CRF intron (hnRNA), or the spliced intron-less variant (spanning exon-intron 
junctions; mRNA) were used to determine transcript levels by RT-qPCR. Blood samples for 
ACTH measurement were collected in ice-chilled 1 ml EDTA-tubes. After centrifugation for 
15 min at 3000 g, plasma (supernatant) was stored at -80°C until analyzed. ACTH levels were 
determined by an ELISA-assay specific for human ACTH (#SG51041; IBL, Hamburg) according 
to the manufacturers’ protocol. The colorimetric readout signal was determined using an 
Optima FluoStar plate reader. 
 
Experiment 7. Effect of TGOT on restraint stress-induced CRTC translocation and CREB 
phosphorylation 
Male rats were infused with TGOT (1nmol / 2µl, 3rd ventricle) or vehicle (Ringer) as described 
in Experiment 7 and in the restraint stress protocol. PVN punches from non-frozen tissue (as 
described in Experiment 4) were treated to obtain separate cytosolic and nuclear protein 
lysates to determine levels of CRTC2 and CRTC3 in both fractions, and pCREB in the nuclear 
fraction. 
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In addition to CRTCs, we assessed the contribution of the JNK – c-Jun signaling pathway to 
the regulation of the CRF gene (King and Nicholson 2007). We hypothesized a modulatory 
cross-talk between OTR signaling and the JNK pathway to regulate CRF gene transcription in 
rats during stress. Rats were placed for 5 or 10 min on an elevated, inescapable platform (25 
cm diameter, 75 cm height), located at 50-70 cm distance from their home-cage. This 
procedure is established in our laboratory as a mild stressor to activate the HPA axis. Control 
animals were left undisturbed in their home-cage to control for the duration of the stressor.  
Brains were removed and the hypothalamic tissue isolated as described in Experiment 2 for 
western blot analysis with the respective JNK antibodies. Detailed assessment of the cross-
talk between OT and JNK signaling was carried out in H32 cells, stimulated with TNFα (50 
ng/ml) or anisomycin (5 µM) as potent stimulators of JNK signaling, and OT (10 -1000 nM). 
 
Experiment 8. Effects of TGOT on FSK-induced CRF hnRNA, CREB phosphorylation, and 
CRTC2/3 translocation in primary neurons, and H32, and Be(2)-M17 cells 
To study TGOT’s effects on CRTC translocation and CRF gene expression in more detail we 
made use of primary neurons, H32 cells, and the human neuroblastoma cell line Be(2)-M17. 
Cells were cultured and stimulated as described above in the material and methods 
paragraph with FSK (Sigma) at 10, 50, or 75 µM, dissolved in 0.1 % dimethylsulfoxide 
(DMSO), or vehicle (0.1 % DMSO in cell culture medium), and TGOT at 10 or 100 nM 
concentration. Time course experiments were carried out in a reverse manner, beginning 
the incubation period at the longest time point (240, 90, or 60 min), and adding drugs when 
appropriate to the remaining cell culture dishes, so that all cells (including non-treated 
controls) were serum-starved for the same amount of time and harvested all at once (time 
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point 0). To allow for comparisons between independent experiments, the values of CRF 
expression, and cytosolic and nuclear CRTC2 and CRTC3 content are expressed relative to 
the maximum level of the Veh + FSK group in each experiment. 
 
Experiment 9. siRNA knockdown of CRTC3 in Be(2)-M17 cells reduces FSK-induced CRF 
transcription, but also blocks the TGOT-induced negative effects on CRF hnRNA 
Be(2)-M17 cells were pre-incubated with specific CRTC2, CRTC3, or negative control oligo #5 
siRNA as described above in the siRNA transfection paragraph. After 12 h of incubation at 
37°C and 95% O2 / 5% CO2, cells were treated with FSK and TGOT for 1h. Half of the petri-
dishes were used for RNA isolation to assess CRF hnRNA, as well as CRTC2 and 3 mRNA 
levels, whereas the other half was used for protein isolation to determine the efficiency of 
the knockdown of CRTC2 and CRTC3 at the protein level. 
 
Experiment 10. TGOT attenuates FSK-induced binding of CRTC3, but not CRTC2 to the CRF 
promoter 
To determine whether changes in CRTC2 and CRTC3 translocation correlate with altered 
CRTC2 and 3 occupancy of the CRF promoter, we immuno-precipitated chromatin from FSK + 
TGOT (10 min) stimulated Be(2)-M17 cells with a CRTC2 or CRTC3 antibody as described 
above in the ChIP paragraph and analyzed the obtained chromatin fragments by RT-qPCR 
with CRF-promoter specific primers. Other known anxiety-related gene promoters, which 
also contain a CRE region, served as controls. 
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Results Part II 
 
Experiment 6. Assessment of the effect of exogenous OT, applied in the 3rd ventricle, on CRF 
gene expression and plasma ACTH 
Vehicle treated / restraint stressed (Veh-RS) rats displayed a rapid increase in CRF hnRNA in 
the PVN with maximal levels observed between 10 and 15 min of restraint, which returned 
to near-basal levels by 30 min. OT delayed this stress-induced response, with peak CRF 
hnRNA values found in oxytocin treated / restraint stressed (OT-RS) rats at 15 min and a 
slower decrease to basal levels (two-way ANOVA; treatment x time F(3;48)= 195,4; p= 0.001, 
Figure 19A). After 10 min of stress, OT-RS rats showed a reduced CRF hnRNA level compared 
with Veh-RS controls (p = 0.001), whereas at the 30 min time point, CRF hnRNA levels of OT-
RS rats were higher than both basal levels and those of Veh-RS animals (p = 0.001). There 
was no difference in CRF hnRNA expression within the PVN between oxytocin treated / non-
stressed (OT-NS) and Veh-NS rats, indicating that OT has no effect on basal CRF expression. 
As CRF controls ACTH release from the pituitary gland, plasma ACTH levels were measured 
as a rough reflection of CRF release. In parallel to the delayed increase in CRF hnRNA 
expression, OT likewise tended to delay the plasma ACTH response to restraint stress (two-
way ANOVA; treatment x time F(3;36)= 3.4; p = 0.032, Figure 19B). In the Veh-RS group, 
plasma ACTH concentrations peaked at 10 min and remained elevated until the end of the 
stressor. In the OT-RS rats, plasma ACTH tended to be lower at 10 min (p = 0.065 versus Veh-
RS), and peaked at 15 min of restraint, thus being significantly higher (p = 0.035) than those 
in Veh-RS animals. At 30 min, ACTH levels of Veh-RS and OT-RS treated rats did not differ (p 
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= 0.109). Thus, OT, when infused into the 3rd ventricle prior to the onset of restraint stress, 
acutely delays the increase of CRF gene transcription following restraint stress, whereas 
effects on HPA axis activity, as measured by trunk blood ACTH concentration, are negligible. 
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Figure 19 OT (1 nmol / 2 µl infused into the 3rd ventricle) delays restraint stress-(RS)-induced CRF gene 
transcription in the PVN (A) and plasma ACTH response (B). A, The stress-induced increase in normalized CRF 
hnRNA levels (Veh-RS) is delayed by an OT infusion 10 min earlier (OT-RS), as is the subsequent return to basal 
levels. B, OT tends to delay the increase in plasma ACTH levels induced by restraint stress, and establishes 
slightly higher peak levels. Under basal conditions, icv OT (OT-NS) was ineffective in all of the experiments. 
Data are mean ± SEM. * p < 0.05 versus Veh-RS group at the respective time point, # p < 0.05 versus respective 
NS group, n = 4 (10 and 15 min), or n = 8 (NS, 30 min) for all figures. 
 
In contrast to the findings above, there were no changes in CRF mRNA levels during the time 
period studied (30 min) in any of the groups tested (Figure 20). Changes may occur at later 
time points, as processing of hnRNA into mRNA takes longer than 30 min (Ma et al. 1997). 
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Figure 20  CRF mRNA levels remained constant and were not affected by both, OT (1 nmol / 2 µl 
infused into the 3rd ventricle) or restraint stress-(RS) in the PVN. Data are mean ± SEM, n = 4 (10 and 15 min), 
or n = 8 (NS, 30 min). 
 
Experiment 7. Effect of TGOT on restraint stress-induced CRTC translocation and CREB 
phosphorylation 
To study the mechanism underlying the effects of OT on CRF gene expression in vivo, we 
examined the translocation of CRTCs following 10 min of restraint stress. As expected, stress 
tended to decrease cytosolic levels of CRTC2 (not significant) and CRTC3 (p = 0.007) 
compared to Veh-NS rats (Figure 21A, C). This reduction was mirrored in the nuclear 
compartment, where CRTC2 and CRTC3 levels were significantly increased (p = 0.03 for both; 
Figure 21B, D). This provides clear evidence for stress-induced activation of CRTC2 and 
CRTC3 and their subsequent nuclear translocation within the PVN. 
Pre-treatment of the stress group with TGOT (TGOT-RS) prevented the reduction of cytosolic 
levels of CRTC2 and CRTC3 significantly compared to RS rats (Figure 21A, C) and, accordingly, 
decreased nuclear levels of CRTC2 (not significant) and CRTC3 (p = 0.026) compared to Veh-
RS (Figure 21B, D). These data suggest that TGOT inhibits the stress-induced activation, and 
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subsequent translocation, of predominantly CRTC3 and to a lesser extent of CRTC2. This 
effect on CRTCs was shown to be region-specific, as no effect of TGOT or stress, on CRTC2 or 
CRTC3 translocation was found in the cortex (data not shown; for region specific CRTC 
expression levels see (Watts et al. 2011)).  
As CRTCs are co-factors of CREB signaling, we assessed whether TGOT inhibits the stress-
induced pCREB phosphorylation. Icv infusion of TGOT did not influence the increase of 
pCREB following 10 min of restraint stress, suggesting that OT regulates CRF gene expression 
through modulation of CRTC translocation, rather than CREB phosphorylation (Figure 21E, F).  
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Figure 21 TGOT prevents the RS-induced translocation of CRTC2 and CRTC3 from the cytosol to the 
nucleus without modifying stress-induced phosphorylation of CREB (pCREB) in PVN protein extracts. TGOT 
(1nmol/2µl, 3rd ventricle) prevents the RS-induced decrease in cytosolic CRTC2 (A), the simultaneous increase in 
nuclear CRTC2 (B) the decrease in cytosolic CRTC3 levels observed after RS (C) and the simultaneous increase in 
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nuclear CRTC3 levels (D). CRTC2/3 levels were normalized for total protein levels by GAPDH (A,C), or Lamin A 
(B,D). The RS-induced increase in nuclear pCREB  is not influenced by TGOT when normalized for total protein 
(E) or total CREB (F) levels. Data are mean ± SEM. *p < 0.05 versus Veh-RS; #p < 0.05 versus Veh-NS, n = 5-7 in 
all groups. 
 
Involvement of JNK in the stress response 
 Another factor that binds the CRF promoter to regulate its gene expression is the 
transcription factor c-Jun, whose upstream kinase is the stress activated MAP kinase JNK. 
We found in a preliminary experiment that even a mild stressor (elevated platform stress) 
increased the level of phosphorylated JNK1 to 135% ± 1.6% (Figure 22) in the hypothalamus 
of male rats compared to non-stressed animals, indicating an active role in the regulation of 
the stress response. The related JNK2 and JNK3 were not activated by the stressor, indicative 
by the very faint bands above pJNK1. 
 
Figure 22  Representative Blot revealing a 135 ± 1.6% increase of phosphorylated JNK1 in the 
hypothalamus of male rats after 10 min of elevated platform stress. The level of total JNK1/2/3 was not altered 
over the time period measured. 
 
 
To further study the crosstalk between the activated OTR and JNK – c-Jun signaling we made 
use of the rat hypothalamic cell line H32.  
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Anisomycin, a strong activator of JNK signaling induced JNK phosphorylation (211 ± 27 % at 
10 min; 785 ± 32 % at 20 min), whereas TGOT alone had no effect. Also, TGOT did not alter 
anisomycin-induced pJNK levels. In addition to the lack of effect on JNK, we found no 
influence of TGOT on the phosphorylation of JNK’s downstream transcription factor c-Jun 
(Figure 23).  
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Figure 23  TGOT does not alter basal or anisomycin-induced pJNK1/2/3, or phospho-c-Jun levels 
in H32 cells A, Representative western blot of TGOT (10 nM) and anisomycin (5µM)-induced JNK1/2/3 
phosphorylation. Anisomycin stimulation for 10 or 20 min induces prominent JNK1/2/3 phosphorylation, 
whereas TGOT has no effect on basal pJNK or on anisomycin-induced pJNK-levels at 10 or 20 min time point. 
The level of total JNK remained constant in the cytosol. B, In line with the lack of effect on JNK, TGOT treatment 
(20 min, 10 nM) did not induce c-Jun phosphorylation in the nuclear compartment. Data are expressed as mean 
± SEM, normalized to total JNK (A), or total c-Jun (B), n = 4. 
 
Taken together, our in vivo results suggest that OT delays the peak of CRF transcription 
activity, and that this effect might be mediated by the regulation of CRTC3, and partly 
CRTC2, translocation, while cross-talk between the OTR and the stress-activated JNK 
pathway is unlikely. 
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Experiment 8. Effects of TGOT on FSK-induced CRF hnRNA, CREB posphorylation, and 
CRTC2/3 translocation in primary neurons and H32 cells  
To study the effects of OT and TGOT on CRF gene transcription and CRTC translocation in 
more detail, we made use of rat primary hypothalamic cells, and the rat hypothalamic cell 
line H32 (Mugele et al. 1993). 
Stimulation of rat embryonic d18 primary hypothalamic neurons with FSK (1 µM) and/or 
TGOT (10 nM) revealed a striking similarity in the pattern of CRF hnRNA expression 
compared with adult rat hypothalamic PVN tissue in vivo. FSK induced a rapid increase of 
CRF hnRNA levels, which peaked at 20-30 min (p < 0.001 for both time points), and returned 
to near-basal levels (p = 0.061) at 90 min. The presence of TGOT in the incubation medium 
reduced the FSK-induced CRF hnRNA-peak to 74 ± 4.6 % at 30 min (p = 0.002). Also, TGOT 
prolonged the duration of FSK-induced CRF gene expression, as CRF hnRNA levels were still 
elevated at the 90 min time point (Figure 24A; two-way ANOVA F(5,84)= 4.6; p < 0.001).  
The protein yield of the primary cultures was too low to analyze CRTC2 and CRTC3 
translocation and CREB phosphorylation by western blotting. Therefore, we made use of the 
immortalized rat hypothalamic cell line H32 (Mugele et al. 1993), because of their 
hypothalamic origin and expression of endogenous OTR. Although these cells have lost CRF 
gene expression, the CREB-CRTC signaling pathway that is known to regulate CRF gene 
expression (Liu et al. 2011), and pathways that are coupled to the OTR, are still intact (Blume 
et al. 2008). In H32 cells, we found no effect of TGOT on the FSK-induced, transient CREB 
phosphorylation, peaking at 10 min and returning to baseline 20 min after the incubation 
started (Figure 24B). Likewise, FSK-induced nuclear CRTC2 levels were not affected by TGOT 
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during the first 60 min after administration (Figure 24C), but a further increase in nuclear 
CRTC2 was found  90 min after the application of both compounds (p = 0.047). 
In sharp contrast, TGOT had profound effects on the FSK-stimulated increase in nuclear 
CRTC3 levels of H32 cells (Figure 24D). FSK alone augmented CRTC3 in the nucleus with a 
peak at 10 min after the onset of FSK stimulation (p < 0.001), and maintained nuclear CRTC3 
levels elevated during the 90 min of incubation (p < 0.001). Treatment of H32 cells with 
TGOT prevented the fast peak that was induced by FSK alone at 10 min (p = 0.007), but 
steadily increased nuclear CRTC3 levels until their maximum was reached at 60 min at a level 
that was about 1.4-fold higher than the peak levels induced by FSK alone after 10 min (p < 
0.001) (two-way ANOVA, F(6,64)= 5.3; p < 0.001). Next, a rapid drop during 30 min annuled the 
differences between FSK- and FSK + TGOT-induced nuclear CRTC3 levels at 90 min. 
Comparable to the lack of effect of TGOT alone on CRF hnRNA in primary neurons (Figure 
24A), we found no effect of TGOT without FSK on nuclear CRTC2 and CRTC3 levels (Figure 
24C,D). 
The data from the restraint stress experiments, together with those obtained in cell culture, 
suggest that OT controls CRF expression through inhibited nuclear translocation of CRTC3 
during stress at early time points, but not under basal (NS or without FSK) conditions. 
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Figure 24.  TGOT (10 nM) reduces the FSK (1µM)-induced CRF hnRNA levels in primary cells, and delays 
FSK-induced increase of nuclear CRTC3 levels in H32 cells. A, In primary hypothalamic cells, the CRF hnRNA 
levels that are augmented by FSK peak between 20 and 30 min of incubation; peak levels were set to 1 to make 
comparisons across multiple independent experiments possible in this and subsequent figures. TGOT reduces 
the magnitude of the CRF hnRNA response, and delays the return to basal levels. B, TGOT does not affect the 
FSK-induced increase of CREB phosphorylation. Data was normalized with total CREB. C, TGOT has no effect on 
the FSK-induced increase of normalized (to Lamin A) nuclear CRTC2 levels until 60 min of incubation. D, TGOT 
delays the FSK-induced normalized (to Lamin A) nuclear CRTC3 levels, but increases these to 1.4 fold higher at 
60 min as compared to the maximum response to FSK alone at 10 min. Two-way ANOVA was performed 
followed by Student-Newman-Keuls post hoc test. * p < 0.05 versus Veh + FSK; # p < 0.05 versus respective 0 
min time point (Veh + FSK, TGOT + FSK groups). n= 5-8 
 
 
Experiment 8.1. Forskolin (FSK) and TGOT dose response and time course experiments in 
human Be(2)-M17 cells 
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To study the effects of OT on CRTC translocation in more detail, we made use of the human 
neuroblastoma cell line Be(2)-M17. First, we assessed the presence of OTR, V1a, and V1b 
mRNA in the cell line. As depicted in Figure 25 Be(2)-M17 cells express the OTR (215 bp 
amplicon), but also V1a (135 bp amplicon) and, although very faint, V1b receptors (128 bp 
amplicon). To exclude activation of the vasopressin receptors by OT, we used from there on 
the specific OTR agonist TGOT exclusively. For this initial experiment we used RNA isolated 
from Veh or OT treated cells to compare receptor mRNA levels after treatment. As expected, 
we found no alterations in receptor mRNA after a 60 min incubation with 250 nM OT. In line 
with literature (Gimpl and Fahrenholz 2001), this preliminary result suggests that gene 
expression of the OTR is not altered by 60 min of OT treatment. However, receptor 
desensitization and/or internalization upon TGOT treatment may occur and further 
experiments to validate the initial results are needed. 
 
Figure 25  Agarose-gel displaying qPCR amplicons of vehicle-or OT stimulated Be(2)-M17 cells. 
mRNA was isolated from stimulated cells (Veh; Ringers, or OT 10 nM for 1h) and analyzed using specific primer 
pairs for the human OTR, V1a and V1b receptor. 
 
In initial experiments, lower doses of FSK (1-10 µM) failed to induce reproducible CRF 
responses. Three independent dose-response experiments using 10, 50, and 75 µM of FSK 
(for comparable doses see (Sala et al. 2000; Liu et al. 2010; Heo et al. 2013)) were performed 
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and 60 min stimulation with 50 µM of FSK induced the maximal and most reliable CRTC3 (p < 
0.001) translocation from cytoplasm (Figure 26C) into the nucleus (Figure 26D, p < 0.001) 
and CREB phosphorylation (Figure 26F, p < 0.001). 
To address if the different affinity states of the OTR are involved in this response  (Gimpl and 
Fahrenholz 2001), we compared two doses of TGOT (10 nM versus 100 nM) in their 
effectiveness to reduce FSK-induced CRF hnRNA levels (Figure 26E). Indeed, FSK increased 
CRF hnRNA levels after 60 min of incubation, and this was significantly reduced by either 
dose of TGOT with no apparent dose dependency (one-way ANOVA F(4;29]= 12.3; p = 0.001). 
Therefore, 10 nM TGOT was used throughout the rest of the experiments. 
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Figure 26. Dose response experiment to determine the optimal dosage of FSK and TGOT-induced 
stimulation of CRTC2 and CRTC3 translocation, CREB activation, and CRF hnRNA expression in Be(2)M17 cells. 
Be(2) M17 cells were treated with 10, 50, and 75 µM FSK for 60 min. For reasons of clear arrangement 10 and 
75 µM data are not shown. A,B, 50 µM of FSK did not alter cytoplasmic CRTC2 content significantly (A, p = 
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0.201) but increased the nuclear content of CRTC2 (B, p < 0.001). C,D, 50 µM FSK induced nuclear translocation 
of CRTC3 (p < 0.001 for cytoplasmic decrease, p = 0.001 for nuclear increase). Cytoplasmic proteins were 
normalized by ß-tubulin, nuclear proteins were normalized by Lamin A. E, 10 nM and 100 nM TGOT were 
equally effective in attenuating the FSK-induced increase of CRF hnRNA. No effect of TGOT on CRF hnRNA levels 
was apparent in the absence of FSK. F, 50 µM FSK increased pCREB levels about 3.5 fold (p = 0.001). Data are 
expressed as mean ± SEM. # p < 0.05 versus Veh group; + p < 0.05 versus Veh + FSK group, $ p < 0.05 versus 
TGOT + Veh group; n = 3 
 
Experiment 8.2. Time course of FSK-induced CRF hnRNA levels and CRTC2/3 translocation in 
Be(2)-M17 cells 
A temporal analysis showed that stimulation of Be(2)-M17 cells with 50 µM of FSK 
augmented CRF hnRNA levels, which reached their maximum after 60 min and remained 
elevated until at least 90 min. Baseline levels were reached at 240 min (data not shown). 
TGOT affected FSK-induced CRF hnRNA (two-way ANOVA F(3,41)= 4.4; p = 0.01) reaching lower 
levels at 60 min (p < 0.001) and 90 min (p = 0.005) after the onset of the incubation. 
Incubation with TGOT alone was without effect on CRF hnRNA levels at any of the time 
points measured (Figure 27A). The FSK-induced phosphorylation of CREB was not affected by 
TGOT (Figure 27B), again suggesting that OT does not control CRF expression by modulation 
of CREB phosphorylation. 
Although FSK increased nuclear CRTC2 levels (p = 0.039) after 10 min of incubation, we did 
not find statistical differences between the effects of FSK on the one hand, and FSK and 
TGOT together on the other (two-way ANOVA, F(3,31)= 2.3; p = 0.103). It is to note that the 
FSK-induced CRTC2-response is relatively short-lived (30 min) in comparison to H32 cells (at 
least 90 min), suggesting a minor importance of CRTC2 in the regulation of CRF gene 
transcription in Be(2)-M17 cells. However, TGOT tended to delay the increase of FSK-induced 
CRTC2 levels in the nucleus, resulting in a delay of the maximum response from 10 to 30 min 
after the onset of the incubation (Figure 27C). This was more evident for CRTC3 (two-way 
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ANOVA; F(4,52)= 2,56; p = 0.05) where TGOT significantly prevented FSK-induced increase of 
nuclear CRTC3 levels during the early phase of the response (p = 0.016), so that the 
maximum response was not reached until 60 min of incubation (Figure 27D).  
Thus, the effects of TGOT on FSK-induced changes in CRF hnRNA levels, CRTC2 and CRTC3 
translocation, and CREB phosphorylation in the human Be(2)-M17 cells, are strikingly similar 
to those observed in the rat hypothalamus, and rat hypothalamic cells. Therefore, we 
concluded that the Be(2)-M17 cells are a suitable model to further study the modulatory role 
of OT on CRTC translocation and the control of CRF gene expression. 
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Figure 27. TGOT delays FSK-induced CRF hnRNA and CRTC3 translocation in Be(2)-M17 cells.  A, CRF 
hnRNA levels peaked at 60 min, and remained elevated until 90 min after the onset of FSK. TGOT attenuated 
the FSK-induced increase at 60 (p < 0.001) and 90 min (p = 0.05) significantly until it paralleled FSK-levels at 120 
min (not shown) and declined similarly to FSK to near basal levels at 240 min (not shown). TGOT was without 
effect in the absence of FSK. B, pCREB levels peaked at 10 min in FSK stimulated cells, with or without TGOT. 
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This peak level returned to almost basal at 30 min, revealing no influence of TGOT on FSK-induced CREB 
phosphorylation. pCREB levels were normalized by total CREB and Lamin A (not shown). The amount of total 
CREB remained constant over time. C, Nuclear CRTC2 levels peak at 10 min after FSK treatment (p = 0.039) and 
return to basal at 30 min, whereas TGOT was without effect. D, FSK-induced nuclear CRTC3 levels peaked at 10 
min (p = 0.009), and were delayed by TGOT until 60 min (p = 0.016), where both reached similar levels. TGOT 
without FSK had no effect on CRTC3 levels. Data are expressed as mean ± SEM. Data are relative to maximum 
response to FSK incubation to make comparison across experiments possible. Representative Western blots are 
shown collectively. * p < 0.05 versus Veh + FSK group; # p < 0.05 versus respective 0 min time point; n = 5-8 
 
 
Experiment 9. siRNA knockdown of CRTC3 in Be(2)-M17 cells reduces FSK-induced CRF 
transcription, but also blocks the TGOT-induced negative effects on CRF hnRNA.  
To determine whether CRTC2 and/or CRTC3 are necessary for the inhibition of CRF gene 
expression by OT, we down-regulated the expression of CRTC2 and CRTC3 by transfecting 
the Be(2)-M17 cells with siRNA oligonucleotides. The CRTC2 siRNA construct down-regulated 
both CRTC2 and CRTC3 mRNA levels by 60 % (p = 0.002) and 20 % (p = 0.019), respectively. 
The CRTC2 mRNA downregulation was mirrored at the protein level (64 %), whereas CRTC3 
protein levels did not change. The CRTC3 siRNA construct specifically reduced both CRTC3 
mRNA and protein levels by 60 %. The non-specific control siRNA oligonucleotide was 
without effect (Table 3). 
 
Table 3 Target specificity of the CRTC2/3 siRNA toward mRNA and protein levels. Data are expressed as mean 
± SEM. SEM are put in parentheses. n = 3 
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Statistical analysis revealed a significant effect of TGOT + FSK treatment (F(3,27) = 33.93; p < 
0.001; Figure 28), and of pre-treatment with siRNA constructs (F(3,27) = 17.4; p < 0.001). 
Student-Newman-Keuls post hoc analysis revealed a significant reduction in stimulated CRF 
hnRNA levels by TGOT in 3 groups, i.e. in untreated (p < 0.001), siCRTC2- (p = 0.005) , and 
control oligo (p = 0.018) pre-treated cells. In contrast, cells that were pre-treated with the 
CRTC3 siRNA construct revealed a less pronounced FSK-induced rise in CRF hnRNA (50% of 
untreated or control oligo pre-treated cells, p < 0.001). Importantly, TGOT treatment was 
without effect on CRF transcript levels in CRTC3 siRNA transfected cells. Due to the 
remaining three-fold increase of CRF hnRNA levels in FSK-treated cells, we can exclude a 
floor effect in the TGOT + FSK group. This shows that CRF gene transcription relies on both 
CRTCs, and that the effect of TGOT on CRF gene expression depends exclusively on CRTC3, 
rather than on CRTC2.   
 
C
R
F  
h
n
R
N
A
 f
o
ld
 c
h
a n
ge
0
2
4
6
8
10


untreated si CRTC2 si CRTC3control oligo


pre-treatm.
Veh + FSK TGOT + FSK
 
Figure 28  Knockdown of CRTC3 reduces FSK-induced CRF hnRNA in Be(2)-M17 cells, and 
prevents the additional negative effect of TGOT on the FSK-induced increase. Treatment of Be(2)-M17 cells 
with FSK + TGOT for 60 min decreased FSK-induced CRF hnRNA as expected (p = 0.004). Pretreatment with a 
negative control oligonucleotide had no significant effect on FSK or FSK + TGOT induced CRF hnRNA levels. 
Pretreatment of the cells with CRTC2 siRNA tended to decrease FSK-induced CRF hnRNA levels, compared to 
cells with no pre-treatment (untreated), whereas TGOT retained its negative effect on FSK-induced CRF hnRNA 
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(p = 0.016). CRTC3 siRNA reduced the FSK-induced CRF hnRNA level significantly about 40 % (3 fold above 
basal; p = 0.003)), whereas TGOT had no additional negative effect on the FSK-induced CRF hnRNA levels (p = 
0.774). Data are expressed as mean ± SEM; * p < 0.05 versus respective Veh + FSK; # p < 0.05 versus untreated 
Veh + FSK; n = 5-8 
 
 
In summary, our data reveals the central role of CRTC3 in CRF gene expression regulation in 
Be(2)-M17 cells, and that OT attenuates CRF gene expression specifically via this factor. 
However, compensatory mechanisms between CRTC2 and CRTC3 cannot be ruled out, and 
might account for the apparent lack of effect of the CRTC2 knock down on CRF hnRNA levels, 
as well as the observed weak expression of CRTC2 protein in Be(2)-M17 cells by means of 
western blotting. 
 
Experiment 10. TGOT attenuates FSK-induced binding of CRTC3, but not CRTC2 to the CRF 
promoter  
To demonstrate that OT affects CRTC3 binding to the promoter of the CRF gene, we 
performed ChIP analyses in Be(2)-M17 cells. We showed that FSK induced binding of CRTC2 
and CRTC3 to the CRF promoter (Figure 29A,B; one way ANOVA, F(3,15) = 10.7; p = 0.001 for 
CRTC2; F(3,19) = 4.4; p = 0.02 for CRTC3). TGOT (10 min, 10 nM) prevented FSK-induced CRTC3 
(p = 0.028), but not CRTC2, binding to the CRF promoter. TGOT in the absence of FSK was 
without effect. This supports the hypothesis that OT mediates the downregulation of CRF 
transcription during stress via CRTC3, but not CRTC2. 
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Figure 29  Chromatin Immunoprecipitation revealed that TGOT decreases FSK-induced binding 
of CRTC3 to the CRF promoter, but not that of CRTC2. A, FSK (10 min, 50 µM, gray bar) induced  a rapid 
increase of CRTC2-CRF promoter-binding (p = 0.002), whereas TGOT treatment had no influence on CRTC2 
binding activity  B, Binding of CRTC3 to the CRF promoter was greatly enhanced by FSK (p = 0.014), but reduced 
to basal (vehicle) levels by treatment with TGOT (p = 0.028). TGOT in absence of FSK was without effect on the 
activity of the CRF promoter. Data are expressed as mean ± SEM, * p < 0.05 versus Veh + FSK group, # p < 0.05 
versus Veh-Veh group; n = 4 
 
 
Preliminary data reveals a potential influence of activated CRTC3 on other anxiety-related 
and CRE-regulated genes. The opioid receptor µ, which has been linked to PTSD, might be 
activated by FSK, and influenced by the presence of OT. The somatostatin gene has been 
shown to be co-expressed and released with CRF (Dulcis et al. 2013) and might also have an 
effect on the release of CRF itself. The PPARγ subunit 1c has been associated with anxiety 
disorders in humans (Sokolowska and Hovatta 2013) and might contribute to the regulation 
of stress and anxiety. Interestingly, the promoter regions of these three genes were also 
immuno-precipitated in our ChIP experiment, indicating that activated CRTCs have bound 
these genes and altered their gene expression. However, the nature of this regulation, and 
its significance, still has to be determined in continuative studies. 
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General Discussion 
In this thesis I have shown some of the intracellular pathways that are coupled to an 
activation of the OTR by its ligand, the neuropeptide OT. Also, the roles that these signaling 
cascades play in emotion (anxiety) and physiology (stress) have been clarified by studying 
the consequences of acute high OT levels in the PVN of rats. For one of these pathways, the 
CREB pathway, it has become clear how an extracellular signal is translated into a molecular 
response at the gene transcription level. Characterization of another pathway, centered 
around MAPK signaling, has provided insight into how an extracellular stimulus gives rise to 
a multitude of intracellular biochemical responses that are necessary to bring about 
behavioral changes. It is also interesting to note that these responses are highly specific, as 
for instance demonstrated by a mismatch of MEK1/2 and ERK1/2 phosphorylation. Such 
specificity could make the development of anxiolytic or stress-protective medication easier 
when a highly specific factor has been identified. On the other hand, it might prove to be 
very challenging to target a specific intracellular pathway that is composed of common 
factors that influence many neuronal processes, but is unique in the assembly of these 
factors. On top of that, I have found that the physiological status of an individual, here the 
reproductive status of female rats, has a profound influence on how an animal (or a human 
being) will respond to a particular pharmaceutical treatment. 
 
1. OT and MAPK signaling in the PVN 
We found that MEK1/2 activity is necessary for the anxiolytic effect of OT in the PVN, 
although this is only the case when OT is infused into the PVN, and not into the ventricular 
system. This is rather surprising, considering that following both infusion protocols, MEK1/2 
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is phosphorylated to more or less the same extent. Apparently, (i) other factors are needed 
for anxiolysis, or (ii) the MEK1/2 molecules that are phosphorylated by OT infused into the 
PVN are different from the ones that are activated following icv infusion. Which of these two 
scenarios applies is not known at the moment. It is, however, possible that the differential 
effects of MEK1/2 phosphorylation depend on the final OT concentration within the PVN. 
When OT is infused directly into the PVN at 0.01 nmol / 0.5 µl, its concentration will be in 
the µM range (taking into account that the concentration infused is 20 µM and that the 
volume of the PVN is approximately 1 mm3 (based on Paxinos atlas)). This would imply that 
the OTR in the high and the low affinity state will be activated. When OT is infused into the 
ventricular system, only a small portion of the OT molecules will likely be able to enter the 
PVN, even when 1 nmol of OT is infused. This would mean that only the high affinity OTRs 
are activated. One could hypothesize that MEK1/2 signaling that is coupled to the OTRs in 
the high affinity state is not involved in the anxiolytic effect of OT, whereas MEK1/2 coupled 
to the OTRs in the low affinity state are. In support of this, I found that icv infusion of OT or 
TGOT altered CRTC3 translocation and CRF expression, which was mimicked by stimulation 
of hypothalamic cells with low nM doses of TGOT and OT. This suggests that OT exerts its 
effects on CRF gene transcription via activation of OTRs in the high affinity state. 
My observation that MEK1/2 is activated upon an infusion of OT or TGOT into the PVN or icv 
suggests that OTR activation is followed by transactivation of the EGFR, as has been shown 
in other cell types (Zhong et al. 2003). This therefore seems to be a common mechanism of 
relaying the extracellular OT stimulus to an intracellular response.  
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1.1 Downstream targets of OT-induced MEK1/2 
What is surprising, however, is that MEK1/2 activation is not accompanied by ERK1/2 
activation in both male and female rats. This is quite remarkable, as ERK1/2 were considered 
to be the only targets of MEK1/2. Interactions of MEK with its substrates (and upstream 
kinases) are organized by several scaffolding proteins including KSR (Stewart et al. 1999), 
MP1 (Pullikuth et al. 2005), and disc-large (Maiga et al. 2011). It seems reasonable to assume 
that MEK1/2, being part of a large signaling complex anchored to scaffolding proteins, could 
physically interact with substrates other than ERK1/2 as well. Indeed, in human monocytes, 
a MEK2 – PI3Kδ pathway has been identified that operates independently from ERK, and 
serves to stimulate the production of an endogenous interleukin 1 receptor antagonist 
(Brandt et al.). Other proteins that directly interact with MEK1/2 are the TGF-β receptor type 
II in a lymphoma cell line (Chen et al. 2011), and tumor suppressor WOXI in lysosomes of 
Jurkat cells (promotes apoptosis in T cell leukemia (Lin et al. 2011)). Also, MEK has been 
found to translocate to and from the nucleus, where it directly phosphorylates the 
transcription factor MyoD in differentiating myoblasts, thus influencing gene transcription 
(Jo et al. 2011). Finally, MEK has been shown to bind the nuclear receptor peroxisome 
proliferator-activated receptor γ (PPARγ), then to export it out of the nucleus, and hence, to 
reduce PPARγ-controlled gene expression (Burgermeister et al. 2007).  
Recently it has become clear that MEK2 can even play an active role in the 
dephosphorylation of ERK1/2, rather than their phosphorylation. During cell migration, 
activated MEK2 serves as a scaffolding protein and binds a RhoGTPase, which, in turn, 
interacts with the isomerase Pin1. Pin1 dephosphorylates ERK1/2 (Nakatsu et al. 2010; Pan 
et al. 2010) and, intriguingly, the expression of Pin1 is upregulated during lactation (DA 
Slattery, unpublished data), a time when the OT system is highly active. Thus, OT induces the 
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activation of MEK1/2-dependent pathways in the PVN; pathways that possibly involve 
substrates that are different from ERK1/2. If so, it seems reasonable to assume that these 
substrates are mediators of the anxiolytic effect of OT, which we showed to depend on 
MEK1/2 in male and female (virgin) rats. Blocking the kinase activity of MEK1/2 with U0126 
in the PVN of female, virgin rats revealed no effects on basal anxiety-like behavior. However, 
U0126 did prevent the anxiolytic activity of exogenous OT. Similar results have been found in 
male rats (Waldherr and Neumann 2007; Blume et al. 2008).  
Again, this shows that MEK1/2 plays a role in anxiety only when it is recruited by the OTR. In 
other words, there seems to be a certain differentiation in the intracellular pathways that 
contain MEK1/2. The function of MEK1/2 depends on what pathway it is in, and which 
substrates it can phosphorylate or which downstream signaling factors it can bind. 
Scaffolding proteins are likely the organizers of such differentiation, as I have argued above. 
 
1.2 Effects of OT on ERK phosphorylation 
The only effect of OT on pERK I observed was the apparent translocation of pERK1 (but not 
pERK2) to the nucleus in lactating animals. This translocation might accommodate the 
changes at the gene expression level necessary to induce neuroplasticity and stable rewiring 
of the neural circuitries that occur in lactation, resulting in physiological, psychological, and 
behavioral adaptations. Thus, it has consistently been reported that the PVN undergoes 
major morphological alterations during the peripartum period. This has been associated with 
increased OT activity, both in the supraoptic nucleus and PVN (Theodosis and Poulain 1989; 
Oliet 2002; Theodosis 2002). The differential effect of reproductive status on ERK1 and ERK2 
adds to the notion that these two closely related MAP kinases exert separate functions in 
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the brain. It has for long been believed that ERK1 and ERK2 are redundant, but elegant 
experiments employing genetic strategies (such as the generation of knockdown, knockout, 
and conditional knock-out mice) have revealed especially ERK2-specific effects on learning 
and memory (Satoh et al. 2007), as well as on the regulation of complex behavior, including 
social behavior (Satoh et al. 2011). Although ERK1 was reported not to influence learning 
and memory (Selcher et al. 2001), a later study using ERK1 knockout mice revealed a specific 
role of ERK1 in synaptic plasticity and drug addiction in the striatum (Mazzucchelli et al. 
2002). Therefore, the translocation that we observed in lactating rats may, at least in part, 
underlie the plasticity seen within the PVN of lactating dams, in addition to the anxiolysis.  
The lack of ERK1/2 phosphorylation when OT is infused icv or directly into the PVN is in 
contrast to an earlier report that describes a 28% (± 23% SEM) increase of ERK1/2 
phosphorylation (Blume et al. 2008). This study further mentioned a lack of effect on ERK1/2 
phosphorylation when AVP, instead of OT, was infused icv. Although there is no convincing 
explanation for the effects reported by these authors, they appear somewhat surprising, 
considering that AVP is known to induce ERK1/2 phosphorylation in astrocytes (Du et al. 
2008), hypothalamic cells ((10nM AVP) (Chen and Aguilera 2010)), and even in V2-expressing 
cultured kidney cells and in vivo (Oligny-Longpre et al. 2012). Also, in the paper by Blume et 
al., the in vitro OT concentration used to stimulate H32 cells was 1 µM, by far exceeding the 
dissociation constant (Kd) of the OTR (1-100 nM), which is almost sure to activate the V1 
receptors expressed by these cells (Chen et al. 2009). To circumvent the non-specific binding 
of OT to the AVP receptors, I have used the highly specific OTR agonist TGOT. Like OT in vivo 
and at low concentrations (1-10 nM) in H32 cells, TGOT did not induce ERK1/2 
phosphorylation. Whatever the cause may be for the different results presented here and 
the previous study by Blume et al., it is clear that MEK1/2, in general, is able to 
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phosphorylate ERK1/2 in the PVN, as blocking MEK1/2 activity by U0126 reduced the non-
stimulated pERK1/2 content in the PVN of virgin female rats. The MEK1/2 – ERK1/2 module 
is, however, not recruited by OTRs.  
To complicate things further, ERK can reside in the nucleus and affect several intracellular 
processes without being phosphorylated and independently from its kinase activity. These 
processes include cell cycle control by inactivation of the regulatory protein retinoblastoma 
(Rb), activation of the transcription factor Elk-1, and even binding to ERK-responsive 
elements on the DNA can occur (for review see Rodriguez and Crespo 2011). A prerequisite 
for these activities is nuclear translocation, which is unlikely to happen following stimulation 
of hypothalamic neurons with OT, since the phosphorylation state of PEA-15 did not change 
in our experiments, so that ERK1/2 remains sequestered in the cytoplasm. 
 
1.3 Effects of the reproductive status on MAPK signaling and anxiety 
The anxiolytic effect of endogenous brain OT during the peripartum period has been well-
documented in female rats (Windle et al. 1997; Neumann et al. 2000; Bosch et al. 2005). My 
observation that an acute, bilateral OT infusion into the PVN of lactating rats did not 
augment anxiolysis further might indicate that during lactation maximum anxiolysis has 
already been reached, as endogenous OT levels are already high (Slattery and Neumann 
2008). Thus, one might expect that blocking the activity of MEK1/2 in lactating rats would be 
anxiogenic, and this turned out to be indeed the case. I like therefore to propose that during 
lactation, an OTR– MEK1/2 – anxiolysis pathway is active. 
Interestingly, while icv OT infusion resulted in increased phosphorylation of MEK1/2 in the 
PVN of virgin rats, OT reduced MEK1/2 phosphorylation in lactating rats. This decrease of 
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phosphorylated MEK1/2 was not accompanied by altered anxiety-like behavior, indicating 
that OT can control MEK1/2 differentially, depending on the reproductive status of female 
rats. This also demonstrates, once again, that pMEK1/2 is not necessarily coupled to anxiety-
like behavior, even when high OT concentrations are present in the PVN. Even more, as OT 
reduces pMEK1/2 levels in the PVN of lactating rats, one might predict that OT recruits 
additional factors in these animals that lead to inhibition of MEK1/2. 
 
1.4 Differences in transcriptional regulation in males and females 
Active MAPK signaling influences the activity of nuclear transcription factors, like the 
transcription factor CREB and its cofactor CRTC. Although the PVN undergoes major 
reorganization during the peripartum period (Theodosis 2002), the signaling cascades that 
induce CREB activation are relatively stable (Shaywitz and Greenberg 1999). One of these is 
the MEK1/2-ERK1/2 pathway. Upon phosphorylation ERK1/2 translocates to the nucleus, 
activates p90rsk or MSK1/2, which phosphorylate CREB to ultimately activate gene 
transcription. However, the lack of ERK1/2 activity I observed in males and virgin females 
excludes this possibility. A related MAPK, p38, is able to activate MSK1/2 as well. Indeed, I 
found p38 to be phosphorylated by an OT stimulus in males. The three-tiered p38-MSK-CREB 
cascade might translate the OT signal into changes in gene transcription, while 
phosphorylated MEK1/2 affects cytosolic targets. This complex adaptation seen in males is 
probably absent in lactating females, where the MEK1/2-ERK1/2 pathway is constantly 
elevated, thereby enabling CREB activation by ERK-p90rsk or ERK-MSK1/2. The observation 
of sex-specific recruitment of intracellular pathways is supported by other studies that reveal 
a differential regulation of CRF, by sex-specific DNA methylation in the PVN upon chronic 
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mild stress (Sterrenburg et al. 2011), or sex-specific phosphorylation of TrkB-ERK1/2 in the 
hippocampus (Hill et al. 2013).  
In summary, the data suggest that hypothalamic CREB is activated by p38-MSK1/2 in males, 
while females (especially lactating females) activate CREB via the activated MEK1/2-ERK1/2, 
or via a yet unknown pathway. 
One common, sex-independent mechanism of transcriptional regulation represents the 
histone kinase activity of MSK1/2. MSK1/2 has been shown to phosphorylate histone 3, 
which induces transcriptional activity (Dyson et al. 2005; Duncan et al. 2006). However, 
histone phosphorylation via MSK1/2 upon OT treatment has not been investigated in this 
work, nor has it been studied elsewhere (Vermeulen et al. 2009). 
 
2. OT release and its influence on the stress response 
As previous studies have shown, OT dampens HPA axis activity when central exogenous or 
endogenous OT levels are high during a long period of time, as observed during the 
peripartum period (Neumann et al. 2000; Windle et al. 2004; Hillerer et al. 2011). 
Accordingly, it appeared that the CRF mRNA levels in the PVN are reduced during this time 
(Walker et al. 2001). Conversely, in OT knock-out mice, CRF mRNA levels are elevated 
(Nomura, Saito et al. 2003). However, here we focused on the acute effects of OT, for 
example such as seen following successful mating in male rats (Waldherr and Neumann 
2007). It is important to consider that OT can be released during or immediately after stress 
in the PVN (Wotjak et al. 1998); although the exact timing of this elevation in available OT is 
not precisely known. I propose that OT release during stress inhibits CRF gene expression, 
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either to reallocate energy away from investment processes (when OT is released during 
stress), or as a negative feedback mechanism (when OT is released immediately after the 
stress). However, the latter is less likely, because in our study OT levels are already high 
before the onset of a stressor, so that negative feedback mechanisms are not yet 
operational.  
Another function of OT release during stress might be to reduce stress via social buffering 
(Smith and Wang 2013). When female monogamous prairie voles were restraint stressed, 
the presence of their male partner reduced anxiety-like behavior and plasma corticosterone 
levels during recovery, compared to females that had to recover in social isolation. This 
effect was mimicked by bilateral intra-PVN infusion of a high dose of OT (100ng/200nl/side) 
in females that had to recover without their partner. Moreover, the beneficial effect of the 
partner could be blocked with an OTR antagonist, suggesting a role for OT in the reduction of 
the stress response in a social context. Whether this social stress-buffering effect of OT is 
related to the inhibition of CRF expression is currently not known. 
However, the delay of CRF expression that I observed in the hypothalamus may not only 
influence the HPA axis, but also other physiological and behavioral effects of stress. CRF 
neurons in the PVN make synaptic contacts with neurons, both CRF-positive and negative, in 
the PVN (Liposits et al. 1985). Some of these contacts involve reciprocal connections 
between CRF and OT cells, suggesting that the effects of OT on CRF expression may be direct 
(Dabrowska et al. 2011). Also, CRF neurons project to various brain regions including the 
ventral tegmental area (Rodaros et al. 2007), hippocampus, and the locus coeruleus 
(Koegler-Muly et al. 1993), where CRF has been shown to be released during stress 
(Valentino and Van Bockstaele 2008). These neurons are a distinct population from those 
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that project to the median eminence to regulate pituitary ACTH release (Reyes et al. 2005). 
CRF release in these brain regions during stress modifies the local microcircuitry, and hence 
the processing of information. This has best been studied in the hippocampus where CRF 
release induces long-term potentiation or dendritic spine retraction, hyperexcitability and 
seizures - depending on the severity of the stressor (Maras and Baram 2012). OT released 
during or immediately after stress may play a role in dampening these detrimental effects 
via the CREB/CRTC3 pathway. 
 
2.1 Regulatory mechanisms of CRF gene transcription 
The regulation of gene transcription as it appears at the CRF gene is controlled at multiple 
levels, i.e. a variety of transcription factors and co-factors has to act in concert to activate 
their specific targets. CRF is mainly regulated by the transcription factor CREB. One 
remarkable observation was that OT influences the stress- or FSK-induced translocation of 
the CREB Co-activator CRTC3, but not CRTC2, as mirrored by the reduced binding of CRTC3 
to the CRF promoter. Data from rats in vivo, primary hypothalamic rat cells, an immortalized 
rat hypothalamic cell line (selected for OTR expression), and human neuroblastoma cells that 
were differentiated to neurons all point in the same direction: less stress-induced CRF gene 
expression, in parallel to delayed CRTC3 translocation, induced by the presence of OT. It is 
especially convincing that the phenomenon occurs in rat as well as human cells, in adult PVN 
tissue punches as well as embryonic rat hypothalamic cells. This shows that the mechanism 
applies no matter what the age of the animal is, and operates both in rats and in humans. 
The only difference between the rat and human cells was that the potentiating effect of OT 
on CRF gene transcription and CRTC translocation observed in rat cells at late time points, 
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was absent in the differentiated Be(2)-M17 human neurons. This might be explained by the 
origin of the cells from bone marrow, where intracellular mechanisms, which would regulate 
CRF expression in hypothalamic neurons, could be absent. Although the human Be(2)-M17 
cells reacted comparable to rat hypothalamic cells in vitro and in vivo at early time points, 
suggesting similar regulating mechanisms across species, we cannot exclude species specific 
differences between rats and humans at later time points. Nevertheless, the strong similarity 
in the early phase of the stress (or FSK)-induced CRF gene expression and CRTC3 
translocation between the rat and human cells made it possible to assess whether CRTC3 is 
necessary for the effects of OT on the stress-induced increase of CRF gene expression in the 
human cells. Indeed, the knockdown of CRTC3, but not CRTC2, prevented the inhibitory 
effects of OT, and the ChIP analysis demonstrated that OT significantly reduced the binding 
of CRTC3 to the CRF promoter. 
Furthermore, it was interesting to note that both, OT and stress lead to CREB 
phosphorylation. While restraint stress appeared as a strong activator of CREB 
phosphorylation, OT induced a rather moderate effect on pCREB. The stress-induced 
phosphorylation of CREB at Ser133 appeared transient, peaking 10 min after the onset of the 
stimulus and coinciding with the maximum nuclear CRTC3 levels, which is followed by CRF 
gene transcription. Interestingly, when both, OT and stress were applied to the animals, OT 
revealed no effect on stress-induced pCREB levels, but reduced CRF hnRNA levels at early 
time points. We observed the same effects in vitro, when the cells were stimulated with 
TGOT alone or in combination with FSK. Our observation that OT (or TGOT) alone leads to 
increased pCREB levels, whereas OT in the presence of stress has no effect, strengthens our 
conclusion that OT mediates its inhibitory effects on CRF gene transcription via a factor 
other than pCREB, and that was found to be CRTC3. While CREB and CRTC are both required 
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for CRF gene transcription to occur, it should be noted that CRTC3 levels plateaued for a 
rather long time period, in contrast to the sharp and short-lived CREB Ser133 
phosphorylation. It has been found, however, that the binding of CREB to the TAFII130 
component of the transcription factor IID complex is independent of CREB Ser133 
phosphorylation, whereas binding of the complex to the CRE is potentiated by CRTCs (Riccio 
et al. 2006; Altarejos and Montminy 2011). In addition, other phospho-acceptor sites of 
CREB, such as the Ca2+-influx-dependent Ser142 and Ser143 residues, which are 
phosphorylated with slightly slower kinetics than Ser 133 (Kornhauser et al. 2002), may 
sustain the activity of CREB. 
Other factors, such as the JNK-activated transcription factor c-Jun, also play a crucial role in 
the transcriptional regulation of the CRF gene. c-Jun activation appears in distinct brain 
regions in a stress- and species-dependent manner (Liu et al. 2004), and is one factor that 
binds the CRF promoter to induce gene transcription (King and Nicholson 2007). We found 
that acute mild stress, such as the elevated platform, induces JNK1 phosphorylation in the 
hypothalamus of male rats. We hypothesized that OT might interfere with the JNK-c-Jun 
pathway to influence CRF gene transcription. By inhibiting JNK signaling, OT could decrease 
phospho-c-Jun levels and subsequently reduce CRF gene transcription. However, no 
interactions between OTR-coupled signaling cascades and the JNK pathway were found, 
which suggests a central role of the CRTCs in the OTR-induced regulation of CRF gene 
transcription. Also, it has been proposed that the regulatory elements on the CRF promoter 
are hierarchically regulated (King and Nicholson 2007). To induce CRF gene expression, the 
activation of the c-Jun binding site can be overcome by other factors that bind the CRE, like 
CREB or CRTCs, so that CRF gene expression is attenuated, or enhanced. However, c-Jun 
binding is necessary for CRF gene expression, regardless of CREB-CRTC binding to the 
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promoter. This might be one explanation for the lack of effects of OT on CRF gene expression 
under basal, non-stressed conditions. 
 
2.2 Other potential targets of CREB/CRTC signaling 
We have shown in this study that OT delays CRF transcription specifically via the CREB 
coactivator CRTC3  during stress. This intracellular arrangement may not be unique to the 
control of the CRF gene, but could likewise apply to the regulation of other anxiety- and 
stress-related genes by OT. For example, the expression of Rgs2 is known to be regulated by 
CRTC3 in human adipose tissue (Song et al. 2010). In the rodent brain and human 
myometrium cells Rgs2 is downstream of OTR activation (Park et al. 2002; Okimoto et al. 
2012) and is likely to mediate anxiolytic effects as seen in rodents (Oliveira-Dos-Santos et al. 
2000; Lifschytz et al. 2012). There are more anxiety- and stress-related genes (Sokolowska 
and Hovatta 2013) that harbor a CRE region in their promoter, including PPARγ-coactivator-
1α, TrkB, and opioid receptor mu1 (B. Jurek, unpublished observation) and could, thus, be 
regulated by OT and CRTC3 as well. 
In summary, this work reveals a delaying effect of OT on CRF gene transcription via the CREB 
coactivator CRTC3, but not via CRTC2. Although both factors get activated by stressors, OT 
exclusively interferes with CRTC3. This finding complements hitherto existing research by 
underlining the potent regulatory function of CRTC3 in CRF transcription, which makes it a 
promising protein to target for the treatment of diseases related to a dysregulated HPA axis. 
However, changes in gene transcription are long term adaptations, hardly influencing the 
acute stress response that appears from seconds to minutes. It lies upon future studies to 
determine if and how OT influences the acute stress response as well. 
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Summary - concluding remarks 
The work presented in this thesis first and foremost reveals the specificity of intracellular 
signaling pathways that are coupled to the OTR in the PVN. This specificity does not only 
refer to the factors involved in each of these, but also reflects the unique recruitment of 
intracellular pathways depending on the physiological condition of the animal. I found 
profound differences in OT-dependent intracellular signaling when comparing female rats in 
different reproductive states (virgin, pregnant, or lactating), and when comparing pathways 
coupled to CRF expression in stressed and non-stressed male rats. Sex-specific differences in 
CRF expression in the PVN can partly be caused by differential expression of CREB-pathway 
associated enzymes, such as CBP and the p300/CBP associated factor (PCAF) (Sterrenburg et 
al. 2011), and this adaptability of the system is likely to account not only for different sexes, 
but also for different reproductive states. 
The question remains if the results of my work can be translated to humans, and can 
contribute to the understanding of anxiety or stress-related diseases. To some extent, the 
evolutionary conservation of the emotion anxiety and its related pathways certainly allows a 
cross-species comparison of genes involved in the regulation of anxiety between humans 
and rodents by means of genome wide expression profiles (Sokolowska and Hovatta 2013). 
For instance, human studies have associated OT with social cognition and social anxiety, and 
recent studies revealed sex-specific differences in the neural (activity in amygdala, striatum, 
and hippocampus) and behavioral responses (tested in the social “Prisoner’s Dilemma” 
game) to intranasal OT (Rilling et al. 2013). However, given that OT is involved in a wide 
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array of processes in the brain, and considering sex-specific and reproductive state-
dependent effects as described above, treatment with OT might cause unwanted side 
effects. Therefore, it is of crucial interest if the involvement of pMEK1/2 in the processing of 
the emotion anxiety represents a target that is specific enough for the pharmacological 
treatment of anxiety disorders, or if targeting MEK1/2 would cause severe side effect due to 
the widespread cellular use of this kinase. Downstream targets of MEK1/2 may be more 
specifically related to anxiety and the processing of stress. One of these stress- and OT-
specific targets could be CRTC3. We do not know how CRTC3 activation is coupled to the 
OTR, and if the activating pathway includes MEK1/2, however, it might be a factor to target 
for the treatment of anxiety disorders. Drugs that target brain proteins, such as CRTC3, are 
in general unspecific for distinct brain regions, whereas brain region specificity is of central 
importance for the regulation of distinct behaviors. Possibly, the distinct expression of CRTCs 
in only a subset of brain regions (Watts et al. 2011) may contribute to the avoidance of 
unwanted side-effects of CRTC-targeting drugs. However, side-effects cannot be completely 
excluded, as CRTC3 is also expressed in the periphery and has been shown to be involved in 
the regulation of energy homeostasis (Song et al. 2010), mitochondrial biogenesis (Than et 
al. 2011) and the production of interleukin 10 (MacKenzie et al. 2013). Although the related 
CRTC1 is expressed exclusively in the brain, Liu and co-workers suggested that it, if at all, 
only plays a minor role in the control of CRF gene transcription (Liu et al. 2010).  
In conclusion, the findings in humans, in combination with the results of my work in rodents, 
emphasize the need to fully characterize the effects of OT in males and females, at different 
physiological states, and at multiple doses, before a widespread clinical application can be 
legitimated. 
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Perspectives 
To fully understand the effects of OT it is crucial to find the downstream target of 
phosphorylated MEK1/2 in the hypothalamus. This cytoplasmic or nuclear target protein 
could be the sought-after cellular regulator that initiates a change in anxiety-related 
behavior. This issue could be addressed by immunoprecipitations of OT-induced 
hypothalamic pMEK1/2 and subsequent identification of the proteins physically bound to it 
by mass spectrometry.  
Also, the precise molecular mechanism that OT recruits to control CRF release in 
parvocellular CRF neurons (these neurons do not express the OTR (Dabrowska et al. 2013)) 
remains somewhat enigmatic. With action potential-mediated release of endogenous OT 
being blocked with tetrodotoxin, the effects of specific OTR agonists (TGOT) and antagonists 
(Manning compound, OTR antagonist) could be tested for effects on CRF neuron intrinsic 
excitability, glutamate and GABA synaptic inputs, but also noradrenergic synaptic 
modulation. 
Related to this question is the nature of the target neurons or brain nuclei of the OTR 
expressing cells, which may be part of a pathway that regulates the physiological expression 
of fear. Target candidates would be the locus coeruleus (mediating sympathetic effects 
during stress (Benarroch 2009)) ventral tegmental area (influences social behavior (Tang et 
al. 2014) in press), and the nucleus of the solitary tract that is known to receive projections 
from the central amygdala (Zardetto-Smith and Gray 1990; Roozendaal et al. 1999) and to 
project, via noradrenergic neurons, to the BNST. The amygdala is involved in the processing 
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of anxiety (Knobloch et al. 2011; Viviani et al. 2011) and is, as the BNST (Dabrowska et al. 
2011), reciprocally innervated with the PVN, forming a regulatory circuit that influences the 
perception and processing of stimuli that lead to stress and anxiety. The method of choice 
would be the expression of channel rhodopsin 2 (ChR2) in OT neurons by stereotaxic 
injection of a ChR2/tdTomato (red fluorescence)-expressing, cre-sensitive adeno-associated 
virus into the PVN of OT-cre mice. These mice are then crossed with CRH-green-fluorescence 
protein (GFP) mice to produce a mouse that expresses ChR2 and tdTomato in OT neurons 
and GFP in CRH neurons. This allows the recording of the response of CRH neurons to optical 
stimulation of OT release and to test for sensitivity to OTR and GABAA receptor antagonists. 
 
Addressing these open questions will contribute to the understanding how stress and 
anxiety are regulated at the cellular level and how this is translated into behavioral and 
physiological responses. 
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Abbreviations 
 
ANOVA analysis of variance 
AVP  Arginine-Vasopressin 
BNST  bed nucleus of the stria terminalis 
Ca2+  calcium 
CBP  CREB binding protein 
c-Fos  cellular- Finkel-Biskis-Jinkins murine osteosarcoma virus homologue 
c-Jun  cellular- Ju Nana (jap. for 17) 
CaMK  Ca2+/Calmodulin activated kinase 
CeA  central amygdala 
ChIP  chromatin immuno precipitation 
CNS  central nervous system 
CRE  Cyclic Adenosylmonophosphat responsive element 
CREB  Cyclic Adenosylmonophosphat responsive element binding protein 
CRF  Corticotropin releasing factor 
CRFR  CRF receptor 
CRH  Corticotropin releasing hormone 
CRTC  CREB transcriptional co-activator (also see TORC) 
DMEM  Dulbecco´s modified eagle medium 
ERK  extracellular signal regulated kinase 
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EPM  elevated plus-maze 
FSK  forskolin 
GAPDH Glycerinealdehyde-3-phosphat-dehydrogenase 
HPA  hypothalamic-pituitary-adrenal 
hnRNA  heteronuclear ribonucleic acid  
icv  intracerebroventricular 
ip  intraperitonal 
JNK  c-Jun-N-terminal kinase 
LDB  Light Dark Box 
MAPK  Mitogen activated protein kinase   
MEK  Mitogen activated ERK Kinase 
mRNA  messenger ribonucleic acid 
MSK  Mitogen and stress activated kinase 
mTOR  mammalian target of rapamycin 
MWU  Mann-Whitney-U-test 
OT  oxytocin 
OTR  oxytocin receptor 
PEA-15 Phosphoprotein-enriched in Astrocytes- 15 kDa 
PKA  protein kinase A 
PKC  protein kinase C 
PVN  paraventricular nucleus 
P38  protein 38 kDa 
Ras  rat sarcoma 
RE  responsive element 
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Rgs2  regulator of G-protein coupled signaling 2 
RS  restraint stress 
RT-qPCR quantitative real time Polymerase chain reaction 
s.c.  subcutan 
SEM  standard error of the mean 
Ser/Thr serine/threonine 
SIK  salt-inducible kinase 
siRNA  small interfering RNA 
SON   supraoptic nucleus 
TBP  TATA-Box binding protein 
TBS-T  Tris-buffered saline - Tween 
TGOT  Thr4-Gly7-oxytocin 
TORC  transducer of regulated CREB activity (see CRTC) 
U0126  MEK-inhibitor 
Veh  vehicle 
V1a/b  Vasopressin receptor 1a/b 
V2  Vasopressin receptor 2 
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German summary - Deutsche Zusammenfassung 
 
Das Neuropeptid Oxytocin (OT) nimmt nicht nur Einfluss auf grundlegende physiologische 
Vorgänge wie zum Beispiel Kontraktion der Uterusmuskulatur oder das Einschießen der 
Muttermilch, sondern moduliert auch grundlegende Verhaltensweisen wie Angst, 
mütterliches oder soziales Verhalten und die Stressantwort des Körpers. Dabei ist die Art der 
Modulation stark kontextabhängig. So wird OT oft als angstlösend beschrieben (Bales et al. 
2004; Blume et al. 2008; Jurek et al. 2012), wohingegen es in bestimmten Gehirnregionen 
(Septum) Angstverhalten verstärken kann (Guzman et al. 2013). Darüber hinaus vermindert 
zentrales endogenes OT die basale und stressinduzierte Ausschüttung von ACTH (Neumann 
et al. 2000), obgleich es in der Peripherie und in Kombination mit bestimmten Stressoren die 
Ausschüttung potenzieren kann (Petersson et al. 1999; Ondrejcakova et al. 2010). Um diese 
divergierenden Effekte verstehen zu können, ist es essentiell die molekularen Faktoren zu 
kennen, die diese Effekte hervorrufen.  
In der vorliegenden Arbeit befasse ich mich mit eben diesen molekularen Faktoren, die –
abhängig vom Kontext – ein bestimmtes Verhalten als Reaktion auf Umweltreize 
hervorrufen. Die Bindung von OT an den Oxytocinrezeptor (OTR) rekrutiert Signalkaskaden 
von proteinaktivierenden Kinasen, mithilfe derer Informationen an verschiedene 
Zellkompartimente weitergegeben werden können. Zum einen werden so schnelle Effekte 
im Zytoplasma der Zelle vermittelt (neuronale Erregbarkeit, Ausschüttung von 
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Neuropeptiden), zum anderen werden Signale in den Zellkern transloziert, die Einfluss auf 
die Genaktivität nehmen und somit längerfristige Effekte hervorrufen können.  
Wie sich zeigte, vermindert eine Infusion von OT direkt in den Paraventrikulären Nukleus 
(PVN) des Hypothalamus weiblicher, unverpaarter Tiere deren Angstverhalten in 
Abhängigkeit der Aktivität der MAP Kinase MEK1/2. Überraschenderweise fanden wir keine 
Aktivierung der nachfolgenden Kinase ERK1/2. Dies ist außergewöhnlich, da bis dato keine 
anderen Zielproteine von MEK1/2 im Hypothalamus bekannt sind. Jedoch scheint MEK1/2 
von zentraler Bedeutung für den angstlösenden Effekt von OT zu sein, da eine Inhibierung 
der Kinase den Effekt von OT blockiert. 
Im Gegensatz zu unverpaarten Weibchen wirkt sich eine OT Infusion in den PVN laktierender 
Tiere vermindernd auf die Aktivierung von MEK1/2 aus, welches in diesem Fall wieder mit 
der nachfolgenden Kinase ERK1 gekoppelt ist, ohne weiter Einfluss auf das Angstverhalten zu 
nehmen.  
Diese Daten zeigen zum einen, dass MEK1/2 nur als Vermittler von verschiedenartigen 
extrazellulären Signalen (wie zum Beispiel OT) dient, seine Aktivität aber keine Rückschlüsse 
auf den Auslöser oder die Wirkung zulässt. Zum anderen wird gezeigt, dass die laut Lehrbuch 
starre Abfolge von MEK1/2 auf ERK1/2 nicht immer zutreffend ist. Vielmehr zeigt sich die 
hohe Dynamik der Rezeptor-gekoppelten Signalkaskaden, wobei verschiedene Signale 
unterschiedliche Effekte über die gleichen Signalkaskaden vermitteln können. 
Ein Schwerpunkt dieser Arbeit liegt in der Regulation des Gens für den Corticotropin 
releasing factor (CRF). CRF ist ein entscheidender Aktivator der Hypothalamus-Hypophysen-
Nebennieren-Achse (engl. HPA axis) und damit eine maßgebliche Kontrollinstanz in der 
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Stressantwort des Körpers. Die Transkription dieses Gens wird unter anderem durch den 
Transkriptionsfaktor CREB und dessen verschiedene Co-Aktivatoren gesteuert. Einer dieser 
Co-Aktivatoren ist CRTC3. Wie ich zeigen konnte, verändert OT die Verfügbarkeit von CRTC3 
im Zellkern. Dies wiederum beeinflusst die Transkription von CRTC3-kontrollierten Genen, 
wie zum Beispiel CRF. In diesem Fall wirkt OT nur als Modulator, da es ausschließlich unter 
Stressbedingungen seine Wirkung entfaltet, auf basale CRF Transkription aber keinerlei 
Einfluss nimmt. Eine Ursache hierfür könnte die hierarchische Regulation der 
Gentranskription sein. Damit CREB und seine Co-Aktivatoren die Transkription initiieren 
können, muss zuerst der stressinduzierte Transkriptionsfaktor c-Jun an den CRF Promotor 
binden. Unter basalen (ungestressten) Bedingungen wäre somit c-Jun nicht aktiv und 
CREB/CRTC können die Transkription nicht modulieren. Unter Stressbedingungen bindet c-
Jun an den Promotor, was CREB/CRTC erst ermöglicht die Gentranskription zu potenzieren 
oder abzuschwächen.  
Der Transkriptionsfaktor CREB wird durch verschiedene Signalkaskaden aktiviert, unter 
anderem durch den klassischen MAP Kinase MEK-ERK Signalweg. Da ERK1 nur in 
laktierenden Tieren aktiv ist, und ERK2 in keiner der Experimente nachweisbare Aktivität 
zeigte, stellt sich die Frage wie CREB durch OT aktiviert wird. Die Phosphorylierung der 
Proteinkinasen p38 und MSK1/2 im PVN von männlichen Ratten deutet auf eine ERK1/2-
unabhängige CREB-Aktivierung hin. Unveröffentlichte Daten unserer Gruppe zeigen zudem 
eine Aktivierung der CaMKIV, die ebenfalls Kinase-Aktivität für CREB aufweist.  
Ebenso konnte ich nachweisen, dass OT spezifisch den CREB Co-Aktivator CRTC3 rekrutiert. 
Dieser Co-Aktivator grenzt das Wirkspektrum des aktivierten CREB auf bestimmte Gene ein, 
indem nur solche Gene abgelesen werden für deren Transkription eben jener CRTC3 
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benötigt wird. Umgekehrt können andere Signale, welche ausschließlich CREB aktivieren, 
und CRTC3 inaktiv belassen, nicht die gleichen Gene aktivieren wie OT. Weitere Co-
Aktivatoren von CREB (CBP, p300, TAF4, CRTC1/2) erhöhen dessen Zielspezifität durch die 
enormen Kombinationsmöglichkeiten einen Gen-spezifischen Transkriptionskomplex zu 
bilden.  
Zusammengefasst habe ich mit dieser Arbeit dazu beigetragen einen Teil des Signalweges, 
ausgehend vom aktivierten OTR über zytoplasmatische Proteinkinasen bis hin zu veränderter 
Genaktivität durch nukleäre Transkriptionsfaktoren, aufzuklären. Die Kenntnis all dieser 
Faktoren, sowie das Verständnis ihrer Rolle in der Entstehung und Regulation von Stress und 
Angst, ist eine grundlegende Voraussetzung zur erfolgreichen und zielgerichteten 
Behandlung von stressinduzierten Angsterkrankungen. 
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